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Summary 
 
About 1.5 billion people are infected with at least one of the soil-transmitted helminths (STH); 
Ascaris lumbricoides, hookworm or Tichuris trichiura. One of the groups most affected by STH 
are school aged children, living under poor conditions in the least developed settings. Whereas 
light infections are typically asymptomatic, moderate and heavy infections with these parasites 
cause severe morbidity. In 2015, the estimated burden of STH infections was 3.4 million disability 
adjusted life years. Preventive chemotherapy (PC), the administration of anthelminthic drugs to 
at-risk populations, is the current strategy of the World Health Organization (WHO). Only in 2015, 
over 1 billion tablets of benzimidazoles (albendazole and mebendazole) were distributed around 
the world aiming to reduce the disease burden caused by moderate and heavy infections. The 
success of PC is largely threatened by low efficacy of the two benzimidazoles in particular against 
T. trichiura and by potential resistance development due to immense drug pressure. Hence, new 
drugs with high efficacy against T. trichiura and new drugs to replace albendazole and 
mebendazole in case of drug resistance are urgently needed.  
The objectives of this PhD were closely related to PC. The first objective was to review and 
meta-analyse the efficacy of the current anthelminthic drugs and to provide the first-time summary 
estimates of egg reduction rates (ERR), the key measurement for anthelminthic drug efficacy. 
From the two benzimidazoles, only albendazole has a satisfactory efficacy against hookworm, 
whereas mebendazole is moderately effective against T. trichiura. Alarmingly, a significantly 
reduced efficacy of albendazole for treating hookworm infections and both against T. trichiura was 
demonstrated. Moreover, the estimated ERRs were doubtful or reduced based on the current 
WHO reference efficacies for monitoring drug resistance. According to WHO, the helminth drug 
efficacy should be calculated using the ERRs based on the arithmetic mean. However, the choice 
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of measurement of central tendency (i.e. arithmetic or geometric) is the subject of current 
discussion, which was extended in this thesis by consulting helminth experts with a questionnaire 
including different infection and treatment scenarios. Based on the expert’s opinion, the arithmetic 
mean does not accurately reflect the egg burden and consequently, drug efficacy. Highest 
agreement with the experts’ opinion was reached with the Hölder and geometric mean, however, 
final conclusions have not yet been drawn since the work is still in progress. 
The review highlighted the compelling need of new drugs against T. trichiura and for the 
simultaneous treatment of all STH species, which was addressed with the next objectives. 
Oxantel pamoate has proven its high trichuricidal activity in two recent clinical trials. In order to 
include oxantel pamoate in large scale PC programs, a weight-independent dose is required.  The 
second objective included a dose-finding trial to evaluate the optimal and a weight-independent 
dose (500 mg) for accelerating the delivery process once oxantel pamoate is used for PC. The 
third objective aimed to evaluate the new Chinese drug tribendimidine in different combinations 
and to investigate the improved efficacy of two triple drug therapies (TDT). In the second clinical 
trial of this PhD thesis, the co-administrations tribendimidine plus ivermectin or oxantel pamoate 
were assessed for non-inferiority to albendazole-oxantel pamoate against hookworm infections. 
Tribendimidine could complement or replace albendazole in case of drug resistance in PC 
programs, since it has a similar efficacy profile. In the third clinical trial, we investigated the 
improved efficacy of albendazole-oxantel pamoate combined with pyrantel pamoate against 
hookworm. A significantly increased efficacy was reached by the TDT, compared to albendazole-
oxantel pamoate, which has currently highest efficacy against any STH species. On the downside, 
even after successful treatment, reinfection is relatively fast for A. lumbricoides and T. trichiura 
and somehow slower for hookworm, which was confirmed with an 18 weeks follow-up study.  
Since particularly drug efficacy estimates rely on accurate diagnostic tools and the current method 
Kato-Katz is limited by low sensitivity for low infection intensity, new diagnostic tools are needed. 
Therefore, the fourth objective included the evaluation of FECPAKG2, a new remote location 
online diagnostic tool, in comparison to Kato-Katz. Despite lower sensitivity and egg recovery 
rates, FECPAKG2 offers the advantage of capturing an image, which can be stored and uploaded 
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onto an internet cloud for later analysis of STH in human stool. An additional study under this 
objective was to explore the Butha-Buthe district in Lesotho as a potential new study site. A lower 
STH prevalence was found, compared to the national survey, indicating that PC is no longer 
required. 
In conclusion, the review indicated the short-coming of the two widely used drugs albendazole 
and mebendazole particularly against T. trichiura and a decreased efficacy over time, resulting in 
doubtful or reduced efficacy, according to the current WHO references. The meta-analysed ERRs 
and the in-depth scrutinized measurement of central tendency call for an adaptation of the WHO 
guidelines, first, of the reference efficacies for monitoring anthelminthic drug resistance and 
second, for the assessment of anthelminthic drug efficacy in terms of ERRs. During this PhD 
thesis two novel drugs were evaluated, which demonstrated high efficacy against T. trichiura 
(oxantel pamoate), A. lumbricoides and hookworm (tribendimidine and pyrantel pamoate). We 
have shown an improved efficacy of different co-administration over single-drugs against any STH 
species. Furthermore, co-administrations could prevent anthelminthic drug resistance since the 
drugs act on different targets. Among the combinations tested in the scope of this PhD thesis, 
albendazole-oxantel pamoate proved the most outstanding efficacy, which was additionally 
increased by adding pyrantel pamoate. Our findings compel the evidence to support an adaption 
of the WHO guidelines towards the use of combination chemotherapy.  
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Chapter 1- Introduction 
 
1.1. Soil-transmitted helminths  
The three major groups of parasitic worms (helminths) include nematodes (roundworms), 
trematodes (flukes) and cestodes (tapeworms). Soil-transmitted helminthiasis is caused by an 
infection with the nematodes Ascaris lumbricoides, hookworm (Necator americanus and 
Ancyclostoma duodenale) and Trichuris trichiura. The helminths are transmitted through feces-
contaminated soil, hence the group’s name: soil-transmitted helminths (STH). Infection with 
STH occurs by larval penetration of the skin (hookworm) or via oral uptake of contaminated soil 
in the case of A. lumbricoides and T. trichiura. STH infections are a major public health concern 
in the poor and most vulnerable populations of Asia, Sub-Saharan Africa and the Americas. The 
prevalence is highest among pre-and school-aged children living under poor conditions in the 
least developed settings [1,2]. Hence, STH belong to the group of neglected tropical diseases 
(NTD) [3].  
 
1.1.1. Global distribution and burden 
Looking back into history, already the old Romans were familiar with various intestinal worms 
including A. lumbricoides [4]. The earliest findings of parasitic worms originate from human 
coprolites and date back to the year 2277 BC [5]. Until recently, STH infection were a public 
health concern in Europe and the United States of America, where hookworm infections were 
responsible for the slowdown of economic growth in the early 20th century [6,7]. In the wealthier 
parts of Europe and USA, helminth infections were brought under control in the mid-20th century 
through improved sanitation and increased awareness. The most striking example was reported 
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from Japan: shortly after the Second World War, the prevalence of A. lumbricoides and T. 
trichiura exceeded 50% [7,8]. With improved socioeconomic conditions, sanitation and water 
supply, health education and treatment of children and adults with anthleminthic drugs, STH 
infection disappeared within a period of less than 20 years [7,8].  
 
 
 
 
 
 
 
 
 
 
 
Most recent estimates about the global STH infection numbers originate from the year 2010 [2]. 
About 5.3 billion people lived in areas of STH transmission, whereas 1.45 billion people were 
infected with at least one of the three STH species (Figure 1) [9]. Considering the world’s 
population of the same year (6.9 billion), more than one out of five people (21%) worldwide were 
infected with one or several STHs (Figure 2). In more detail, the highest infection numbers were 
reported for A. lumbricoides (819.0 million people1), followed by T. trichiura (464.6 million) and 
hookworm (438.9 million). Despite the highest reduction of STH prevalence over the past two 
decades, Asia continues to have the highest prevalence of STH infections, followed by Sub-
Sahara Africa and South America [2]. Likewise, the STH prevalence in Sub-Sahara Africa 
decreased from the year 2000 onwards, which might be associated with socioeconomic 
development and intensified control programs [10].  
 
1https://esa.un.org/unpd/wpp/index.htm 
Fig 1. The global prevalence of soil-transmitted helminths. (adapted from Pullan et al., 2014.) 
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In Eastern Europe, STH are still endemic in the native population of Albania, Armenia, Slovakia 
and Turkey, where helminth infections are associated with extreme poverty and poor sanitation 
[11–13]. Because of political instabilities and numerous violent conflicts, in 2015, the number of 
displaced people reached their highest numbers since the Second World War. About 65 million 
people were forcedly displaced, in particular coming from the Middle East and Africa [14]. 
Europe is facing the largest refugee movements since the WWII, which are mainly caused by 
illegal wars in the Middle-East initiated by the United States and its military allies (i.e. NATO-
partners and Saudi Arabia) [14–16]. With the large movement of immigrants from STH endemic 
countries, STH infections attract the attention of the European health authorities. A study from 
Germany reported STH infections in unaccompanied minor refugees and showed the necessity 
for screening and treating new arrivals, which are most vulnerable [17,18].  
Non-specific symptoms are associated with an STH infection, which complicates the estimation 
of the global disease burden and the number of deaths attributed to STH infections. 
Furthermore, soil-transmitted helminthiasis are often co-endemic with malaria, an often fatal 
disease of major public health importance [19]. Therefore, the number of deaths specifically 
caused by soil-transmitted helminthiasis are consequently highly varying across publications 
and range from 10‘000 to 135‘000 deaths per year [20]. Most recent estimates from 2015 
reported a number of 2’700 deaths attributed to A. lumbricoides [21], while no estimates for 
hookworm and T. trichiura were  given. In the same report, an estimated 54‘200 deaths are 
Figure 2. Global numbers of soil-transmitted helminth infections and disability adjusted life years (DALY).  
References: 1 (https://esa.un.org/unpd/wpp/index.htm), 2 (Pullan et al., 2014), 3 (Murray et al., 2012), 4 (GBD 2015 DALYs and HALE Collaborators, 2016) 
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attributed to iron-deficiency anaemia (IDA), which is also associated with malaria and hookworm 
[22]. 
For the year 2010, the global burden of STH infections was 5.2 million disability adjusted life 
years (DALY) [23]. Based on the latest estimates from 2015, a lower burden of 3.4 million 
DALYs was estimated [24]. In more detail, hookworm caused the main burden of 1.8 million 
DALYs, followed by A. lumbricoides with 1.1 million DALYs and T. trichiura with 0.5 million 
DALYs. Despite twice the infection rates for A. lumbricoides, the hookworm burden is higher 
due to IDA [22,25]. Generally speaking, DALY estimations are variable and influenced by the 
estimation of a range of factors, i.e. the disability weight and likelihood for hookworm caused 
anaemia. Consequentially, the DALYs caused by hookworm range from 1.8 million [24], over 
3.2 million [23] or up to 4.1 million [25] depending on the publication.  
 
1.1.2. Life cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Life cycle of soil-transmitted helminths.  
← An infected child is defecating in open 
space and releasing the eggs (T. trichiura, 
hookworm and A. lumbricoides), which 
survive in the soil. 
↓ Within the host eggs/larvae develop into 
adults, mate and start laying eggs. 
→ Individuals get infected by ingesting 
the eggs via food, the work in 
contaminated surroundings or active 
skin penetrating by the larvae (e.g. 
hookworm) 
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Large numbers of STH eggs are released by infected humans and reach the soil via open 
defecation (Figure 3). The eggs of A. lumbricoides and T. trichiura and the larvae of the two 
hookworm species (N. americanus and A. duodenale) develop in the soil to the infective stage.  
Humans are infected by accidentally ingesting the eggs of A. lumbricoides and T. trichiura. 
Once A. lumbricoides eggs developed into larvae, they migrate out of the intestine to the liver 
before entering the lungs. Next, they penetrate the alveolar space and end up in the pharynx. 
After the larvae get swallowed, they reach the small intestines and develop into adults, which 
are able to produce eggs after 9-11 weeks [1,26,27]. T. trichiura eggs moult within the host 
before the larvae travel to the colon and develop into adult worms [1]. 
The two hookworm species, N. americanus and A. duodenal moult twice in the soil until they 
develop into the infective larval stage (L3), which is able to penetrate human skin (N. 
americanus and A. duodenale) or gets orally ingested by humans in case of A. duodenale 
[1,28]. Post infection, the larvae migrate to the lungs, pass over the epiglottis and continue the 
migration to the upper smaller intestines. 4-7 weeks after entering the host, hookworm adults 
are able to produce eggs [1,28–30]. 
 
 
 
 
 
 
 
 
 
 
 
Local STH transmission is determined by the micro-climate and the soil properties. Because of 
the strong outer shell of A. lumbricoides and T. trichiura eggs, they are more resistant to 
Figure 4. The mean intensity and prevalence of soil-transmitted helminths (Ascaris lumbricoides, Trichuris 
trichiura and hookworm) according to the age class. (Figure from Truscott et al. 2014 [33]) 
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environmental influences and survive several months in the soil, in contrast to only a few weeks 
for the hookworm larvae [19,31]. Factors including temperature, pH, light etc., have an influence 
on the larval development. For example, N. americanus hatch only between 15oC and 35oC [32]. 
A. lumbricoides and T. trichiura are most prevalent in school-aged children, while the age 
specific epidemiology of hookworm differs. Likewise, high prevalences are found in school-aged 
children and highest infections are commonly in adults (Figure 4) [33].  
 
1.1.3. Clinical symptoms 
Based on the egg counts of the duplicated Kato-Katz thick smear, the World Health 
Organization (WHO) classifies STH infections into three categories; light, moderate and heavy 
[34]. The morbidity is strongly associated with the number of worms infecting a host. It is 
unknown if light infections are associated with morbidity [2], while moderate and heavy 
infections cause severe morbidity [35]. The prevalence is not necessarily associated with 
morbidity, however moderate and heavy infections are more predominant with higher 
prevalence. The major morbidity caused by adult hookworms is blood loss, induced by the adult 
worms feeding on blood in the gut. A. duodenale feeds more blood than N. americanus, which 
results in ten times more blood loss [36] and a greater amount of IDA [37]. The ingestion of A. 
duodenale can provoke the so-called Waka syndrome, which is characterized by nausea, 
vomiting and pharyngeal irritation [1,30]. The migration of A. lumbricoides larvae through the 
liver and lungs induce different symptoms including pneumonitis. Pneumonitis could result in 
asthma, cough, substernal pain, fever and eosinophilia [38] or even deathly [39]. Moderate T. 
trichiura infections lead to diarrhoea, vomiting, headache, weight loss, whereas heavy infections 
cause bloody diarrhoea, severe anaemia, chronic dysentery, rectal prolapse and colitis [1,40].  
 
1.1.4. Helminth therapy  
The “hygiene hypothesis” was developed in 1989 and claims that with improved living standards 
and hygiene conditions, the risk of developing an allergic reaction is increasing [41]. With more 
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careful hygiene practices and the sterilization of the environment, humans are less exposed to 
helminths, bacteria, viruses or fungi. With a lack of exposure to external pathogens, especially 
early in life, it is hypothesized that the human immune system is rendered hyper-sensitized to 
non-pathogenic substances and host endogenous molecules and cells. Subsequent 
epidemiological studies supported this concept by demonstrating that proper immune system 
activation in early human development plays an important role in shaping the immune system 
and the suppression of allergic reactions [42]. For example, a childhood infection with T. 
trichiura was shown to reduce the prevalence of allergen skin test reactivity and eczema later in 
life [43]. A systematic review and meta-analysis revealed a reduced risk for asthma for 
individuals with a hookworm infection, which was positively association with infection intensity 
[44]. Knowing this, therapies with helminths for autoimmune and other inflammatory disorders 
have been evaluated. While helminth therapy indicated promising results in animal models, 
studies in humans were less confirmatory. In clinical trials, two helminth species have been 
evaluated as therapy: T. suis and N. americanus [45]. T. suis is a common parasite of pigs and 
rarely infects humans, which remains only for a few weeks and is self-limiting. In one study, the 
ingestion of T. suis eggs by Crohn’s disease patients, where the eggs were repeatedly ingested 
for several weeks, a high response rate and eventually remission were demonstrated, which 
was hypothesized to be due to the inhibition of intestinal inflammatory mechanisms [46]. 
However, further studies with T. suis as therapy for Crohn’s disease and ulcerative colitis 
showed contradictory results. A Phase 2 trial with T. suis against Crohn’s disease was even 
stopped at an early stage because of the lack of efficacy [45]. The treatment approach with N. 
americanus showed even less promising results [45,47]. The discrepancy between the animal 
and human studies is likely due to dosing; in most of the cases, significantly higher doses of 
helminths were used in animals, which would not be safe for humans [45].  
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1.2. Control programmes – preventive chemotherapy  
Preventive chemotherapy (PC), the administration of anthelmintic drugs to at-risk populations 
without prior diagnosis, was endorsed in 2001 by the World Health Assembly resolution 
WHA54.19 [48]. Member states for which STH is a public health problem, were urged to control 
morbidity with PC programs (Table 1).  
 
Year Org. Resolution Content Aims 
International resolutions 
2001 World Health 
Assembly  
WHA54.19 [48] WHO founds Department 
for NTD  
- Endemic countries start preventive 
chemotherapy 
- 75% of school-aged children are treated 
until 2010 
2012 WHO, WB, 
B&MG, etc. 
London Declaration on 
Neglected Tropical 
Diseases [51] 
Increase in funding of 
research and drug 
donation by the 
pharmaceutical industry  
- Eliminate or control 10 NTDs by 2020  
- Control morbidity of STH by 2020 
- Sustain or expand drug access programs 
(e.g. preventive chemotherapy) 
- progress reports using scorecards are 
provided annually on 
www.unitingtocombatntds.org 
World Health Organization – STH recommendations 
2006 WHO Preventive chemotherapy 
for human helminthiasis 
[52] 
Manual for health 
professionals and 
program manager 
Annual treatment of school-aged children for 
countries with STH prevalence 20%-50% 
and bi-annual for ≥50%  
2008 WHO Monitoring anthelminthic 
efficacy for STH [53] 
Manual for assessing 
anthelminthic drug 
resistance 
Monitoring anthelmintic drug resistance 
using the arithmetic or geometric FECRT 
2012 WHO Accelerating work to 
overcome the global 
impact of neglected 
tropical diseases [49] 
A roadmap for 
implementation of STH 
control programs 
By 2015; 50% of preschool and school-aged 
children receive PC and 100% of affected 
countries have a plan of action 
By 2020; 75% of preschool-aged and school-
aged children receive PC and 100% of the 
effected countries reach 75% coverage  
2012 WHO Eliminating soil-
transmitted helminthiases 
as a public health 
problem in children  
[50] 
Progress report 
2001−2010 and strategic 
plan 2011−2020 
Goal: Reduce the prevalence of STH 
infections of moderate and high intensity 
among school-aged children below 1% by 
2020 
Objectives: 100% countries start deworming 
by 2015 and 100% of countries reach a 75% 
coverage by 2020 
2013 WHO Assessing the efficacy of 
anthelminthic drugs 
against schistosomiasis 
and STH [34] 
Updated guidelines  Detailed guidelines to harmonize including 
indicators of efficacy, sample size, follow-up, 
diagnostic method, resistance monitoring, 
statistical analysis and interpretation of data 
2017 WHO  Guideline: Preventive 
chemotherapy to control 
STH infections in at-risk 
population groups [54] 
Global, evidence-
informed 
recommendations for 
preventive chemotherapy 
Recommendation: PC with annual or 
biannual albendazole or mebendazole for 
young children, pre-and school-aged 
children, adolescent, non-pregnant women 
and pregnant women (after first trimester)  
Annual WHO Weekly epidemiological 
record – soil-transmitted 
helminthiasis progress 
reports  
Report about the number 
of children treated per 
year in PC programs 
Progress report including the number of 
distributed albendazole and mebendazole 
Tablets and the achieved coverage of PC 
Table 1. International resolution with an impact for soil-transmitted helminth (STH) control programmes and 
recommendations by the World Health Organization. 
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In 2012, WHO released the roadmap to guide the implementation of NTD control and 
elimination programs including recommendations for STHs [49]. In the same year WHO 
released a progress report and strategic plan for STH control (and schistosomiasis), after failing 
the initial goals of the WHA54.19 resolution. The corrected goals included the expansion of PC 
to 50% of pre-and school-aged children in need for regular treatment by 2015 and to 75% by 
2020 for eliminating STH as a public health problem [50]. 
 
 
 
 
 
 
 
 
 
Inspired by the WHO roadmap, a collaborative control program (London Declaration on 
Neglected Tropical Diseases) was launched in 2012. More than 70 pharmaceutical companies, 
governments and global health organisations endorsed their commitment to combat NTDs [51]. 
The pharmaceutical companies pledged to continue the donations of albendazole and 
mebendazole. In 2014, about 900’000 doses albendazole and 135’000 doses of mebendazole 
were donated to treating STH and LF [55]. In 2015, the overall coverage with PC reached 
48.6% preschool-aged children and 64.7% for school-aged children in need for treatment 
(Figure 4) [56].   
 
 
 
 
Figure 5. Population requiring (A) and receiving (B) PC against soil-transmitted helminths in 2015. (adapted from 
http://apps.who.int/gho/cabinet/pc.jsp) 
B A 
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1.3. Limitation of preventive chemotherapy 
The success of PC to control soil-transmitted helminthiasis is threatened by three major 
limitations. First, commonly school-aged children are treated in PC programs against STH [57]. 
However, most recent WHO guidelines from 2017 include young children, pre-and school-aged 
children, adolescent girls, non-pregnant women of reproductive age and pregnant women after 
the first trimester in hookworm or T. trichiura endemic areas with anaemia as a severe public 
health problem [54]. Whereas older recommendations also included adults with a high 
occupational risk [50]. To date, most countries only treat school-aged children on a regular 
base. Considering hookworm prevalence increases with age [33], the expansion of PC to 
adolescent and adults could be a strategy for hookworm endemic settings.  
The second limitation of PC is the low efficacy of the two main benzimidazoles, albendazole and 
mebendazole. Both drugs reveal high efficacy in terms of cure rates (CRs) and egg reduction 
rates (ERR) against A. lumbricoides. A systematic review and meta-analysis from 2008 [58], 
indicated the moderate efficacy of albendazole against hookworm (CR: 72%) and low efficacy of 
pyrantel pamoate (31%) and mebendazole (15%) [58]. The main challenge of PC, however, is 
the low efficacy of albendazole (CR: 28%) and mebendazole (CR: 36%) against T. trichiura. 
Since the last review about anthelminthic drug efficacy, almost a decade has passed and new 
clinical trials were conducted, whereof one was hinting even lower CRs against T. trichiura for 
albendazole (CR: 3%) and mebendazole (CR: 12%) [59]. Hence, the first objective of this PhD 
thesis was to update the systematic review by using a new network meta-analysing approach 
and to provide summary estimates for ERRs, the key parameter for anthelminthic drug efficacy 
(page 24, objective 1). For measuring anthelminthic drug efficacy and to monitor drug 
resistance, which is detected by a decrease in efficacy compared to a reference efficacy for 
albendazole or mebendazole, the arithmetic ERR are recommended by the WHO (Table 1) [34]. 
However, the choice of measure of central tendency (i.e. arithmetic or geometric mean) for 
calculating ERRs is a longstanding discussion among human and animal parasitologists [60–
62]. A side project of this PhD thesis was to further investigate the measurement of central 
Chapter 1 - Introduction  PhD-thesis W. Moser 2017 
 
11 
 
tendency to recommend one of the mean, however, the work is still in progress and part of it will 
be discussed.  
Even after successful treatment, the protection is only transient and reinfections in high endemic 
settings occur quickly. Six to 12 months after successful treatment with albendazole or 
mebendazole, pre-treatment levels are reached for A. lumbricoides and T. trichiura, while 
reinfection with hookworm tends to be slower [63–65]. Most epidemiological reinfection studies 
can only provide inaccurate estimation of T. trichiura reinfection data since an effective 
treatment against T. trichiura is lacking. In the framework of this PhD, a 18 weeks follow-up 
study for estimating the reinfection was conducted after the successful treatment with different 
drug combinations by Speich and colleagues (page 24, objective 3) [66]. 
Third, there are no effective new drugs to replace the current anthleminthic in case of 
resistance. In veterinary medicine, resistance against anthelminthic drugs has been shown 
relatively quickly after the initial approval of several drugs [67,68]. For example, only nine years 
after the approval of levamisole for sheep, resistance was reported in 1979 [67]. Despite the 
increased use of anthelminthic drugs in PC against STH, no resistance in human medicine has 
been found to date. In veterinary nematodes, the frequent use of benzimidazole led to 
resistance, which was caused by a single nucleotide polymorphism in the parasite’s β-tubulin at 
position 200. Diawara and colleagues showed the same substitution in T. trichiura recovered 
from humans in Kenya and Panama, which might explain the low efficacy of the two 
benzimidazole against T. trichiura [69].  
 
1.3.1. Promising drugs 
Given the limitations of current treatments, new drugs and drugs with higher efficacy particularly 
against T. trichiura are warranted. In the framework of this PhD thesis, the efficacy of the two 
novel drug candidates tribendimidine and oxantel pamoate were assessed in three clinical trials 
(see page 24), and hence I will briefly introduce these drugs.  
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1.3.1.1. Tribendimidine 
During the mid-1980s, tribendimidine was developed as a wide-ranging anthelminthic drug in 
China by the National Institute of Parasitic Diseases in Shanghai. The first data about 
tribendimidine were published exactly 3 decades ago, in 1987 [70]. After a series of pre-clinical 
and clinical trials, tribendimidine was approved as a human anthelmintic by the Chinese Food 
and Drug Administration in 2004 [71]. Today, tribendimidine is the only new developed 
chemotherapeutical antiparasitic drug in the past 30 years, however it does not yet have market 
approval outside of China [72]. 
The mode of action was explored in Caenorhabditis elegans, where tribendimidine was 
classified as an L-type nicotinic acetylcholine receptor agonist (nAChR), similar to levamisole 
and pyrantel pamoate (Table 2) [73]. These findings were later revised with experiments in 
Oesophagostomum dentatum and A. suum, where tribendimidine caused depolarization 
antagonized by the nicotinic mecamylamine in the body muscles of the helminths. This indicated 
that tribendimidine is rather an agonist of muscle B-subtype nAChR [74]. Hence, the mode of 
action differs from levamisole and pyrantel pamoate.  
Tribendimidine has demonstrated an excellent safety profile in clinical trials from China [75]. The 
drug was well tolerated and patients showed no abnormalities in routine blood and urine tests, 
hepatic and renal functions, and ECG examinations [71]. Moreover, all studies until 2013 
reported only low numbers of adverse events for the recommended single dose treatment (200 
mg for children and 400 mg for adults) and adverse events were even lower for children than 
adults [75]. Post-approval, further studies confirmed the large anthelminthic spectrum of 
tribendimidine, including activities against more than 20 nematode (e.g. Enterobius vermicularis 
[76,77]), trematode (e.g. Taenia spp. [78]) or cestode (e.g. Opistorchis viverrini [79,80] and 
Clonorchis sinensis [81]) species. Against STH, tribendimidine has a similar activity spectrum 
compared to albendazole, i.e. excellent activity against hookworm and A. lumbricoides. In more 
details, a weight-independent dose of 400 mg for 3 consecutive days resulted in a CR of 89.5%  
against hookworm [82]. Two phase IV clinical trials examined the efficacy of tribendimidine 
against hookworm in children and adults with a dose regimen of 200 mg and 400 mg, 
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respectively. A similar high efficacy was found in children (CRs: 72.7 – 84.5% [83]) and adults 
(CRs of 72.2 – 93.1% [84]). Since tribendimidine revealed high CRs against hookworm and A. 
lumbricoides [75] and a somehow lower CR against T. trichiura, further studies should focus on 
the combination of tribendimidine with a partner drug against T. trichiura. To combine 
tribendimidine with a trichuricidal drug (i.e. ivermectin or oxantel pamoate) and to evaluate 
tribendimidine as alternative drug to albendazole in case of drug resistance was the goal of one 
clinical trial conducted during this PhD thesis (page 24, objective 3).  
 
1.3.1.2. Oxantel pamoate 
In 1974, oxantel pamoate was introduced on the market [85]. The combination of oxantel 
pamoate combined with pyrantel pamoate (Quantrel; Pfizer) is approved for human use in 
Colombia, Peru and the Philippines, however, Quantrel is no longer produced (Kopp and Keiser 
2017, unpublished). Both, oxantel pamoate and pyrantel pamoate belong to the 
tetrahydropyrimidines. While pyrantel pamoate has a high activity against A. lumbricoides and 
hookworm, oxantel pamoate is only active against T. trichiura. They are fast acting 
anthelminthics, which selectively bind to the gated (N-subtype) acetylcholine receptor ion-
channels of nerves and muscles (Table 2) [86] and cause spastic paralysis of nematodes until 
the worms are expelled. Oxantel pamoate is very poorly absorbed and hence, the concentration 
in the caecum and colon could be attained without the risk of systematic reactions [87]. 
Extensive biochemical, hematologic and urine examination did not reveal any drug related 
changes [88]. All studies from the past century and two recent clinical trials described 
predominantly low adverse events [59,66,88–91].  
Oxantel pamoate is of particularly high interest due to its unprecedented high activity against T. 
trichiura. An early study from 1976, reported CRs of 93% and 100% after treating the patients 
with a weight-dependent dose of 20 mg/kg. With only half of the dose regimen (10 mg/kg), the 
CRs dropped to 56.6% and 77%, respectively [88,96]. Several decades later, Speich and 
colleagues resumed the work with oxantel pamoate for treating human trichuriasis. They 
reported a lower CR of 26.3%, with an administered dose of 20 mg/kg and in combination with 
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albendazole increased CRs of 31.2% and 68.5%, respectively [59,66]. Considering that the goal 
of the WHO to reduce moderate and heavy infections, the ERR is the key parameter of 
anthelmintic drug efficacy [49,34]. In contrast to the moderate CRs, the ERRs reported by 
Speich and his team were as high as 93.2% [66].  
 
 
Oxantel pamoate administered in combination with albendazole reached ERRs of 99.2% and 
96%, respectively [59,66]. In light of these results, oxantel pamoate is currently the most 
efficacious drug candidate against T. trichiura. Because the effect of oxantel pamoate is limited 
to T. trichiura, a combination with a partner drug (i.e. albendazole) could reach high efficacy 
against any STH. To continue the work on oxantel pamoate and further explore its advantages 
was the major goal of this PhD thesis.  Hence, three randomized clinical trials (page 24, 
objective 2 and 3) including oxantel pamoate were conducted in the past three years; a dose-
finding trial and two exploratory trial including oxantel pamoate co-administrations (i.e. with 
tribendimidine, albendazole, pyrantel pamoate and mebendazole). 
 
 
Class  Drug  Mode of action  Cause to parasite Ref 
Benzimidazole  Albendazole, 
Mebendazole 
Inhibition of microtubule 
polymerization by 
selective binding to the β-
tubulin  
Destruction of cell 
structure, death of 
parasite 
[92] 
Avermectin  Ivermectin Agonist of glutamate-
gated chloride channels in 
nerve and muscle cells  
Paralysis and death [93] 
Imidazothiazoles 
 
Levamisole L-subtype nAChR agonist. 
Binding to the nAChR on 
body wall muscles 
Spastic paralysis of 
worm, expulsion of 
parasite 
 
[94] 
Tetrahydrophyrimidines Pyrantel 
pamoate 
L-subtype nAChR agonist. Spastic paralysis of 
worm, expulsion of 
parasite 
[95] 
Oxantel 
pamoate 
N-subtype nAChR 
agonist.  
Spastic paralysis of 
worm, expulsion of 
parasite 
[86] 
Tribendimidine  Tribendimidine B-subtype nAChR 
agonist. 
 
Spastic paralysis of 
worm, expulsion of 
parasite 
[74] 
Table 2. Mode of action of the currently used and from two potential anthelminthic drugs. 
Chapter 1 - Introduction  PhD-thesis W. Moser 2017 
 
15 
 
1.3.2. Drug combinations  
Two different strategies could lead to effective treatments against all three STH; the 
development of new drugs and the combination of new and old drugs. Most anthelminthic drugs 
against human STH were developed and approved for veterinary medicine. Apart from the 
currently used anthelminthics, an array of veterinary drugs have been discussed for their 
potential to treat human soil-transmitted helminthiasis [97]. Because only very few drugs are 
currently in the anthelminthic drug pipeline, the combination of old and new drugs might be a 
step forward. The advantage of drug combinations are i) the increased efficacy compared to 
single drugs and ii) the increased protection against drug resistance due to the combined drugs 
acting on different targets [98]. Only a few new drugs have been evaluated in combination with 
the drugs from the WHO List of Essential Medicines against STH (Table 3) [99].  
Drug combination Reference  A. lumbricoides  Hookworm T. trichiura 
ALB-MEB Namwanje et al. 2011 
 [100] 
CR   46.1 
 ERR   93.2 
 Speich et al. 2015 [66]  97.5 47.8 8.4 
  99.9 92.7 51.6 
ALB-IVR 
 
 
Speich et al. 2015  
[66] 
CR 98.0 50.0 27.5 
ERR >99.9 95.4 94.5 
Knopp et al.  
2010 [101] 
CR 92.9 66.7 37.9 
ERR >99.9 95.9 91.1 
Ndyomugyen et al. 2008 
[102] 
CR - 92.6 70.6 
ERR - 63.9 - 
Belizario et al. 2003 
 [103] 
CR 78.1 - 65.1 
ERR 99.5 - 97.5 
Beach et al. 1999 
 [104] 
CR 100.0 100.0 79.6 
ERR 100.0 100.0 68.0 
MEB-IVR Knopp et al. 2010  
[101] 
CR 100.0 25.7 55.1 
ERR 100.0 50.0 96.7 
ALB-DIE 
 
Belizario et al. 2003 
 [103] 
CR 77.5 - 19.2 
ERR 96.6 - 79.4 
ALB-OXP  Speich et al. 2014  
[59] 
CR 94.4 51.4 31.2 
ERR >99.9 95.6 96.0 
Speich et al. 2015  
[66] 
CR 97.9 45.5 66.3 
ERR 99.9 90.9 99.5 
ALB-NIT Speich et al.  
2012 [105] 
CR - 85.7 16.0 
ERR - - 54.9 
ALB-OXP-PYP Shichun et al. 1989 [106] CR 95.0 92.6 92.9 
ERR 100.0 99.3 97.3 
MEB-OXP-PYP 
 
Sinniah et al.  
1980 [91] 
CR 100.0 66.7 81.0 
ERR 100.0 85.7 93.5 
Table 3. The efficacy of different combination with albendazole (ALB), mebendazole (MEB), ivermectin 
(IVR), diethylcarbamazine (DIE), oxantel pamoate (OXP), nitazoxanide (NIT), pyrantel pamoate (PYP). 
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The combinations albendazole with diethylcarbamazine [103] and nitazoxanide [105] showed no 
improved efficacy against T. trichiura and hence, no further clinical trials were conducted. 
Contradicting results were reported for the combination of the two most widely used drugs 
albendazole and mebendazole; compared to mebendazole monotherapy one study showed 
improved [100], while another study did not show improved efficacy against T. trichiura [66]. A 
study from Knopp and colleagues indicated the potential of combining ivermectin with 
albendazole or mebendazole [101]. The combination with mebendazole reached a high efficacy 
against T. trichiura.  
Further studies with albendazole plus ivermectin indicated similar results against all three STH 
[66,102–104]. However, the most promising results were derived from two clinical trials that 
tested the combination of albendazole and oxantel pamoate [59,66]. This combination has 
currently the highest efficacy against any STH, which might even be improved by adding 
pyrantel pamoate [91], which was the goal of one clinical trial (page 24, objective 3) realized 
during this PhD thesis. 
 
1.4. Integrated control approach 
PC might be able to reduce moderate and heavy infections, however given its limitations the 
elimination of STH might not be possible. With an integrated approach, i.e. with extended PC, 
improved water, sanitation, hygiene (WASH) and health education, the interruption of STH 
transmission might be feasible. Japan implemented a similar approach and was able to 
eliminate the initially high STH prevalence within 20 years [7,8]. Because improved WASH is 
integral to reducing poverty, promoting equality and supporting socioeconomic development for 
poor and vulnerable populations, drinking water and sanitation were included in the ‘Millennium 
Development Goals’ [107] and the successive ‘Sustainable Development Goals’ [108].  
WASH promotes the prevention of open defecation with the installation of ventilated-improved 
pith latrines and a faecal disposal management, which decreases the contamination of soil, food 
and hands with STH eggs from infected people. Improved hygiene practices, i.e. hand-washing 
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with soap before eating, after using toilets and the wearing of shoes, could lead to reduced 
transmission [109]. Indeed, two systematic reviews reported lower odds of STH infections with 
increased access and use of sanitation facilities [110,111]. Although not all studies including 
WASH interventions have shown an immediate reduction in STH prevalence [112], WASH has 
an important impact on many different pathogens, including enteric bacteria, intestinal protozoa 
[113] and several NTDs [109].   
 
1.5. Diagnostics  
Today’s STH research is highly dependent on an accurate diagnostic method for estimating 
prevalence, evaluating infection intensities, assessing helminth drug efficacies in clinical trials or 
for monitoring drug resistance [50,114,115]. WHO is currently recommending the duplicate 
Kato-Katz method, which is the basis for the infection intensity classifications into light, 
moderate and heavy infection according to the egg counts [116]. The Kato-Katz method was 
developed almost half a decade ago [34,117] and is not without limitations. The main limitations 
are the low sensitivity for low infection intensities [118], which leads to bias towards false 
negative results [118], followed by the disintegration of hookworm eggs after one hour [119] and 
the short sample storage time [120]. With the addition of multiple samplings, the sensitivity of 
Kato-Katz thick smears can be slightly increased [121–124].  
 
 
 
 
 
In the successive steps from morbidity reduction to transmission control to the elimination of 
STH, different characteristics for the diagnostic method are of importance [114]. For morbidity 
control, the major importance is simplicity and low costs. Kato-Katz is a good tool for these 
settings and the low sensitivity for light infections is an acceptable trade-off (Figure 6). Kato-
Sensitivity of diagnostic method 
Infection intensity 
Figure 6. Association between the infection intensity in an endemic area and the required sensitivity of a 
diagnostic method. High infection intensities are already detected with a low sensitive method, while micro-
infections require highly sensitive methods. (adapted from Bergquist et al., 2009a) 
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Katz requires only little preparation time and equipment, which still allows for the quantification 
of eggs in stool. The preparation of a single Kato-Katz thick smear requires about 20 minutes 
and costs around 1.7$ [123]. Apart from Kato-Katz, several other techniques with comparable 
sampling and time effort have been developed (ether concentration, McMaster and Mini-
FLOTAC) or are still under development (FECPAKG2) [123,125–127]. The last objective of this 
PhD thesis (page 24), was to evaluate the new diagnostic tool FECPAKG2 in the framework of a 
clinical trial. FECPAKG2 is an online, remote location diagnostic tool, which is used in veterinary 
medicine and currently under development for human use (Figure 7). The FECPAKG2 method 
comprise sample preparation (1), the capturing of an image from a cassette filled with the 
sample (2), storage of the image in an internet cloud and marked-up of the image using a 
software (3).  
 
 
 
 
 
 
 
 
Moving forward to transmission control in low infection intensity settings, diagnostic tools with 
increased sensitivity are necessary (Figure 6) [114]. A potential candidate is the FLOTAC 
system. A review and meta-analysis of the currently literature revealed the highest sensitivity for 
FLOTAC (92.7%), whereas for Kato-Katz, the sensitivity depended on the sampling effort and 
ranged from 74-95% [118]. The more steps a country has taken towards elimination, the higher 
the importance of predicting an infection correctly (positive predictive value). The focus is 
currently on different molecular methods, which are developed towards the detection of micro-
infection, such as real time polymerase chain reaction [128]. However, these methods are time 
consuming, require costly laboratory equipment and highly skilled laboratory technicians. 
cassette 
Sedimenter 
cylinder 
MICRO-I 
Marked-up image 
Figure 7. FECPAKG2 system.  
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1.6. Study sites 
1.6.1. Tanzania 
Two clinical trials of this PhD were conducted on Pemba Island, Tanzania. The Zanzibar 
archipelago is situated in the Indian Ocean close to the cost of Tanzania and includes apart 
from smaller, the two major islands Unguja and Pemba (Figure 7). In Zanzibar, large-scale 
administration of anthelminthic drugs (i.e. albendazole or mebendazole) started in the mid-
1990s, because the STH prevalence exceeded 90%. Annually, albendazole or mebendazole 
was distributed among school-aged children [129]. Despite regular administration of 
anthelmintic drugs since decades, the STH prevalence remains high. In two recent clinical trials 
of Speich and colleagues the T. trichiura prevalence in school-aged children exceeded 90% 
[59,66]. 
 
 
 
 
 
 
 
 
 
 
 
The remaining high prevalence, good infrastructure and skilled team of the Public Health 
Laboratory – Ivo de Carneri, present an ideal setting for epidemiological studies and clinical 
trials. The two clinical trials conducted during this PhD thesis, profited from the local leaders, 
field and laboratory workers with long-term experience. For the first study in 2014, two primary 
schools were determined by the local collaborators; Mbuzini and Matale (Figure 7). Two years 
Figure 7: Included primary and secondary school on Pemba Island, Tanzania.  
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later, the four secondary schools were chosen as clinical trial site; Tumbe, Wingwi, Wesha and 
Mizingani.   
 
1.6.2. Côte d’Ivoire  
One part of a clinical trial of this PhD thesis was located in Tanzania and Côte d’Ivoire. In Côte 
d’Ivoire, the southern district Agboville and with the two villages Azaguié and Rubino were 
chosen as study site (Figure 8).  
In 2014, the population of the Agboville district reached almost 300’000 inhabitants, whereas 
around 22’000 people lived in Azaguié and 36’000 people in Rubino [130]. Azaguié is co-
endemic for STH and schistosomiasis (Schistosoma mansoni and S. haematobium) and was 
already the study setting of multiple epidemiological studies and clinical trials [131–133].  
 
 
 
 
 
 
 
 
 
 
 
1.6.3. Lao People’s Democratic Republic 
NTDs are still a major public health concern in Lao People’s Democratic Republic (PDR). 
Highest prevalences are found for Opisthorchis viverrini, followed by STH, lymphatic filariasis 
and schistosomiasis [134]. The last clinical trial, which was conducted during this PhD was 
situated in the Luang Prabang district in Lao PDR. Two secondary (Xomphou and Namthouam) 
Figure 8. Included villages of the Abgoville district in Côte d’Ivoire.  
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and two primary and secondary schools combined (Nayang and Nakhone) were selected. A 
previous, country wide survey, indicated high hookworm prevalence (43%) for the Luang 
Prabang district [135]. Additionally, children from the primary school of Namthouam (Phonmany) 
were screened for hookworm. Due to a misunderstanding with the teachers, all children 
received anthelminthic treatment during the screening process and the school had to be 
excluded from the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6.4. Lesotho 
In 2015 an unpublished NTD survey from the Ministry of Health in Lesotho reported high T. 
trichiura prevalence in the Butha-Buthe district of Lesotho. For re-assessing STH prevalences 
and for evaluating the Butha-Buthe district as a potential study site for clinical trials, a small 
epidemiological study was conducted during this PhD thesis (page 24, objective 4). The 
prevalence was assessed in six primary schools (Marakabei, St Charles, Lebesa, Lekopa, 
Khukhune and Damaseka) (Figure 10).  
 
Figure 9. The primary and secondary schools included in Lao People’s Democratic Republic.  
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Figure 10. The primary schools included in the cross-sectional study in the Butha-Buthe district in Lesotho.  
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1.7. Aim and objectives 
The current standard approach against STH is PC with anthelminthic drugs. The goal of this 
PhD thesis was closely related to the limitations of PC. The major aim was to review and meta-
analyse the efficacy of the current anthelminthic drugs and to further evaluate the promising 
drug oxantel pamoate and tribendimidine. Additional objectives comprised the evaluation of a 
new diagnostic tool and to evaluate Lesotho as a potential clinical study site. In more detail, the 
following objectives were specified to accomplish these goals:  
 
1. Updating the evidence about the current anthelminthic drug efficacies: To review and 
meta-analyse the efficacy of the most commonly used anthelminthic drugs in PC programs 
(chapter 2). 
2. Assessing the efficacy of different doses of oxantel pamoate against T. trichiura to be 
able to calculate a weight independent dose: To assess the efficacy and safety of different 
oxantel pamoate doses in school-aged children infected with T. trichiura on Pemba Island, 
Tanzania (chapter 3). 
3. Assessing different drug combinations against STH and reinfection: To assess the 
efficacy and safety of i) tribendimidine-ivermectin and tribendimidine-oxantel pamoate (chapter 
4a) and i) pyrantel pamoate-oxantel pamoate and albendazole-pyrantel pamoate-oxantel 
pamoate (chapter 4b) against hookworm and concomitant helminth infections. Moreover, to 
assess the reinfection rate after treatment with different drug combinations (chapter 4c).  
4. Exploring novel diagnostic tools and potential study sites: To compare the novel 
diagnostic tool FECPAKG2 to Kato-Katz (chapter 5a) and to evaluate the potential of a new study 
sites (chapter 5b). 
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Chapter 6 - General Discussion 
 
6.1. Rationale and objectives  
About 5.3 billion people are living at risk and 1.24 people are infected with at least one of the 
soil-transmitted helminths (STH), i.e. Ascaris lumbricoides, hookworm and Trichuris trichiura  
[1]. To control STH infection, the current strategy by the World Health Organization (WHO) is 
preventive chemotherapy (PC), the administration of anthelminthic drugs to at-risk populations, 
to reduce the burden caused by moderate and heavy infections [2]. In 2014, more than one 
billion doses of albendazole or mebendazole were distributed in the framework of STH and 
lymphatic filariasis control programs [3]. The success of PC is threatened by the low efficacy of 
the anthelminthic drugs, particularly against T. trichiura [4] and the potential development of 
drug resistance [5]. The main focus of this PhD thesis was to review the performance of the 
currently available anthelminthic drugs and to further assess the two new drugs, oxantel 
pamoate and tribendimidine, which are potential candidates for PC.  
Almost a decade has passed since the efficacy of anthelminthic drugs have last been reviewed 
and meta-analysed [6] and new evidence from clinical trials has accumulated in the meantime. 
Hence, the first objective of this PhD thesis was to update the review with a ‘network meta-
analysis’ approach (chapter 2). For estimating anthelminthic drug efficacy, there is an on-going 
debate about the preferred measurement of central tendency – i.e. arithmetic or geometric 
mean - for calculating the egg reduction rates (ERR). Among experts, there is no consensus 
and only vague arguments led to the recommendations of the arithmetic mean by WHO [5]. 
With a questionnaire including various scenarios of egg burdens and drug efficacies, a panel of 
helminth experts were asked for their interpretations, however, the work is still on-going and 
some results are presented within this discussion.  
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Oxantel pamoate has proven its trichuricidal activity in two recent trials [7,8]. For accelerating 
the delivery process in PC, a fixed dose of oxantel pamoate would be required. For the second 
objective, we evaluated the optimal dose and assessed a weight-independent dose of oxantel 
pamoate against T. trichiura in the first clinical trial of this PhD thesis (chapter 3).  
Combination chemotherapy has two major advantages; i) improved efficacy over single drugs 
regimens and ii) the delay of drug resistance, since the drugs act on different targets. The third 
objective included two clinical trials with different combinations and a study to assess 
reinfection after treatment with drug combinations. A new Chinese drug, tribendimidine, has 
excellent anthelminthic efficacy supported by over a decade of approved use in China [9]. 
Tribendimidine has a similar efficacy profile compared to albendazole and could complement 
albendazole in PC to prevent drug resistance or replace albendazole in case of confirmed 
resistance. In the second clinical trial (chapter 4a), tribendimidine was evaluated in two African 
settings, as mono- and co-administration therapy (with ivermectin or oxantel pamoate) against 
hookworm and concomitant helminth infections. In a third clinical trial, the improved efficacy 
against hookworm of the triple drug therapies (TDT) albendazole-pyrantel-oxantel pamoate 
compared to the co-administration of albendazole-oxantel pamoate was assessed (chapter 4b). 
After successful treatment with anthelminthic drugs, reinfection occurs particularly fast for A. 
lumbricoides and T. trichiura and somehow slower for hookworm [10]. The low efficacy of the 
current drugs cumbered the exact T. trichiura reinfection measurement among existing studies. 
Hence, after treatment with different combinations we investigated the reinfection 18 weeks post 
treatment (chapter 4c).  
An accurate diagnostic technique is the base of all research on STH. Since Kato-Katz, the 
currently recommended method, [11] is used for almost half a decade [5] and has several 
limitations, new diagnostic tools are warranted. The fourth objective, included the diagnostic 
comparison of Kato-Katz with FECPAKG2, a novel diagnostic tool, developed for veterinary 
medicine (Chapter 5a). Since past four clinical trials including oxantel pamoate and different 
combinations [7,8,12,13] were mainly conducted on the same Island (Pemba, Tanzania), a 
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small epidemiological study was carried out in Lesotho, for estimating the prevalence and 
evaluating Lesotho as a potential new study site (chapter 5b). 
 
Since the specific topics are already discussed within the publications, I would like to discuss 
the obtained results in a broader context. Based on the expertise I have gained in the past three 
and a half years, I would like to offer following points for an in-depth discussion: 
 
1. The advantage of the review and network meta-analysis  
2. Application of the review and drug efficacy measurements in the light of current WHO 
recommendations  
3. Review of old and new drugs and combinations 
4. Efficacy of the tested drugs  
5. Preventive chemotherapy – a debate and outlook 
6. Challenges of STH diagnostics 
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6.2 Review of the efficacy of current anthelminthic drugs 
Almost a decade has passed since the only review and meta-analysis of anthelminthic drug 
efficacy was published [6]. In the meantime, new evidence from clinical trials has accumulated 
and new methods for meta-analysing drug efficacy have been developed. Hence, the first 
objective of this PhD thesis was to update the review about anthelminthic drug efficacy by 
applying a network meta-analysis and to provide summary estimates of the ERRs, the key 
summary estimate for anthelminthic drug efficacy. In these chapters, the advantages of the 
‘network’ approach are discussed and our review results are compared to two other reviews. 
 
6.2.1 Advantages of the new review  
Anthelminthic drug efficacy is measured qualitatively by cure rates (CR) or quantitatively by egg 
reduction rates (reduction of egg counts; ERR). Once a country is moving towards elimination, 
the cure of individuals gains on importance and therewith the CRs are used as an outcome 
measure. Since there is a long way to go to reach elimination, the current aim of WHO is to 
reduce the burden of moderate and heavy infections; therefore, the quantitative ERRs are the 
key measurement of anthelminthic drug efficacy [5]. In the review published during this PhD 
(chapter 2), ERRs were meta-analysed for the first-time and by applying a network meta-
analysis, a larger number of studies could be included. Traditionally, meta-analyses include all 
clinical trials with direct estimates of an active drug compared to placebo. For example, the 
review of Keiser and Utzinger [6] meta-analysed all clinical trials with albendazole and placebo 
or mebendazole and placebo. In contrast, a network meta-analysis is able to provide indirect 
estimates via the direct estimates of the included studies. In more details, from clinical trials 
including a direct comparison of drug A versus B and other trials with drug A versus C, the 
indirect treatment effect of drug B versus C is estimated by the network meta-analysis [14]. With 
this approach, studies with two or more active drugs can be used, which increased the number 
of included studies for our review by 11 for CRs and by 13 studies for ERRs. Different models 
exist among network meta-analysis, summarizing binary variables from studies with two or more 
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drugs. We have chosen the model from Kessels and colleagues [15] for our review because of a 
special advantage: the possibility of including clinical trials with only one eligible treatment arm. 
For each study the model is reconstructing the original dataset based on sample size and case 
numbers, before pooling the results of all studies with one, two or more treatment arms. This 
resulted in additional 23 and 16 studies for the meta-analysis of CRs and ERRs, respectively.  
Until recently only the review from Keiser and Utzinger [6] existed, whereas in 2017, three 
different reviews, including ours, were published. A review from Janssen Research & 
Development [16] about the efficacy of a single-dose mebendazole was published just before 
our review [17]. Shortly after, WHO released new guidelines for PC, including data from an 
unpublished, internally conducted, systematic review and meta-analysis [18]. The results of the 
three reviews are presented in Table 5 and discussed below. 
 
The review of Janssen (Mrus et al. [16] ) estimated the average ERRs from all identified and 
only placebo-controlled studies, while WHO (Joseph et al., unpublished [18]) included the 
average ERRs of epidemiological and clinical studies and in a subgroup, ERRs from studies 
following the recommended WHO methodology.  
For A. lumbricodies, similar ERRs were estimated for mebendazole by the three (Janssen, 
Swiss TPH and WHO) and albendazole by the two reviews (Swiss TPH and WHO). The ERR of 
mebendazole against hookworm were lowest in the review from Swiss TPH (61.0%) and for the 
placebo-controlled studies from Janssen (61.2%). Contradictory, 7.2 to 15.5 percentage-points 
higher ERRs were reported by WHO depending on the included studies. Against T. trichiura, 
highest mebendazole ERRs were summarized by Janssen, while WHO and Swiss TPH 
 Mrus et al. 2017, Janssen 
review [16] 
 Moser at al. 2017, 
Swiss TPH [17]  
 Joseph et al. 2017, unpublished, 
WHO guidelines [18] 
 All studies Placebo controlled    All studies WHO methodology  
Ascaris lumbricoides 
Albendazole    98.5  98.7 99.9 
Mebendazole 97.9 98.1  98.0  98.3 97.6 
Hookworm 
Albendazole    89.6  89.8 92.4 
Mebendazole 72.0 61.2  61.0  68.2 76.5 
Trichuris trichiura 
Albendazole    49.9  69.7 64.4 
Mebendazole 72.5 86.8  66.0  69.0 69.3 
Table 5. A comparison of albendazole and mebendazole egg reduction rates from three reviews published in 2017. 
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presented similar results. Only Swiss TPH and Janssen presented summary estimates for CRs, 
whereof the latter review presented lower CRs from all studies against A. lumbricoides (96.2% 
versus 92.6%), hookworm (32.5% versus 25.5%) and T. trichiura (42.1% versus 27.6%) (data 
not presented). 
The reviews from WHO and Swiss TPH estimated the efficacy of albendazole and ERRs were 
found comparable against hookworms. For T. trichiura, WHO reported almost 20%-points higher 
ERR for the main and 15%-points higher ERR for the subgroup analysis, compared to the low 
ERR of 49.9% estimated by the Swiss TPH.  
The review from Janssen and WHO applied a simple pooling approach to summarize the ERRs 
without any precision estimates. In the main analysis, both included epidemiological and clinical 
studies with either albendazole or mebendazole, while the subgroup analysis done by WHO 
included only placebo controlled trials or trials following the WHO recommendations. On the 
contrary, the review of Swiss TPH included exclusively randomised controlled trials, applied a 
network meta-analysis, considered the measure of central tendency for estimating the ERRs 
(i.e. arithmetic, geometric or unknown) and presented precision estimates for the ERRs. To sum 
up, the advanced statistical methods applied by the review from Swiss TPH led to more credible 
estimates, compared to the weaker method used for the review from Janssen and WHO. That 
being said, the leap to the conclusion by the WHO, that the ERRs of albendazole and 
mebendazole are well above the reference threshold [5] and sufficient to control the morbidity 
caused by STH infections [18], should be taken with precautions - the ERRs of mebendazole 
against hookworm and albendazole against T. trichiura of the more comprehensive review from 
the Swiss TPH are considerably lower.  
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6.3. Application of the review results and new efficacy 
measures 
The two publications, namely the review of the efficacy of current anthelminthic drugs (Chapter 
2) and the progressing work about the recommendations of a measure of central tendency for 
ERRs might have a considerable impact on the current WHO guidelines. Firstly, the estimated 
ERRs by the review should be considered as reference values for monitoring anthelminthic drug 
resistance and secondly, the recommended measure of central tendency (i.e. the geometric 
mean or Hölder mean) should be considered for calculating anthelminthic drug efficacy. The 
justification will be given in this chapter together with further background on anthelminthic drug 
resistance.  
 
6.3.1. Anthelminthic drug resistance and application of the review results 
With the up-scaling of PC the selective drug pressure on STH populations increases, potentially 
leading to anthelminthic drug resistance [19]. In veterinary medicine, livestock holders have 
faced frequent and rapid resistance selection against the major anthelminthic drugs [20,21], 
including multi-drug resistance in strongyle parasites [22]. For helminths with veterinary 
importance, resistance against a new drug is already present in a population prior to the first 
treatment [23]. After treatment, assuming a drug is optimal, all susceptible worms are killed and 
resistant worms start to produce eggs until re-infection. How fast resistance spreads depends 
on multiple factors, i.e. treatment frequency, the use of only single drug-regimens, under-dosing, 
mass treatment, etc. In more detail, high annual deworming frequency or lower frequency over a 
longer time period is associated with resistance development in animals [24]. Furthermore, 
farmers used single-drugs in high frequency until the drugs failed after a few years [24]. Under-
dosing could lead to resistance, e.g. if animals are treated with same dose independent of their 
weight or sub-curative doses [25]. The disadvantage of mass treatment is the survival of only 
resistant worms. By moving the livestock to a new field, which is often done by farmers to 
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reduce reinfection, resistant worms lack the competition with wild types and resistance spreads 
faster [26].  
While practices described above have led to resistance in veterinary medicine, different 
treatment approaches are used against human helminthiasis, which might have unintentionally 
prevented resistance in human medicine until now. In contrast to veterinary medicine where 
100% animals are dewormed, mass drug administration for humans only reaches less than 80% 
of population in need. The remaining people are absent during treatment due to various 
reasons, such as work, sickness, disregard, pregnancy etc. After the first treatment round the 
motivation to participate declines in both uninfected and infected people, since infected people 
likely experience less symptoms. Hereby, the pool of wild type worms remains larger and 
outcompetes resistant types, and therefore prevents drug resistance in humans [24].  
The potential development of resistance is threatening the few available drugs for PC and 
represents the trade-off between the necessity of up-scaling PC and the increased drug 
pressure. Current PC programs are reaching mainly school-aged children and to a reduced 
extend preschool-aged children [27]. However, previous and most recent WHO guidelines 
include the treatment of young children (24-59 months), non-pregnant adolescent women, 
women in reproductive age (not pregnant), pregnant women (after first trimester) [18] and adults 
with an occupational risk [2]. Considering the previous and more recent WHO 
recommendations, PC should be applied annually (prevalence ≥20%) or biannually (prevalence 
≥50%) to almost the entire population in endemic settings. Keeping in mind the fact that the 
treatment of all animals with anthelminthic drugs led to resistance, the PC recommendations 
should be applied with precaution.  
Obviously, this increases the importance of monitoring anthelminthic drug resistance. Since 
well-established resistance markers for human STHs do not exist, the change in efficacy 
(ERRs) of albendazole and mebendazole compared to a reference ERR (for albendazole or 
mebendazole) could be used to monitor drug resistance according to WHO guidelines [5]. For 
example, after assessing the ERRs in a given setting they are classified compared to a 
reference, as satisfactory (equal or higher ERR), doubtful (<10 percentage points below 
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reference) or reduced (>10%-points below reference, table 6) [5]. In the absence of a 
systematic review and meta-analysis of ERRs at the time the guidelines were written, the 
reference ERRs were based on two multi-country studies [5,28,29]. In the light of the WHO 
recommendations, the ERRs and estimates for the year 1995 and 2015 deriving from our review 
[17] were interpreted accordingly (Table 6).  
 
Against A. lumbricoides, the ERRs and the estimates for 1995 were well above the reference 
efficacy for albendazole and mebendazole. Strictly interpreted, the mebendazole estimates for 
2015 would be classified as ‘doubtful’. For the treatment of hookworm, the efficacy of 
albendazole (89.6%) and mebendazole (61.0%) are classified as ‘doubtful’. Moreover, the 
estimated albendazole ERR for 2015 is more than 10%-points below the recommendations, 
classified as ‘reduced’ efficacy and potentially indicating drug resistance. Since the average T. 
trichiura infection intensity of the included studies was above 800, the reference ≥50 was taken 
as suggested by two publications [28,30] for albendazole and the ERR and estimates for 2015 
were classified as ‘doubtful’, whereas the ERRs of mebendazole were satisfactory. 
One question arises in the light of the reference and estimated ERR from our review [17]; are 
the doubtful or reduced ERRs of albendazole and mebendazole attributed to anthelminthic drug 
  Albendazole  Mebendazole 
  ERR 95%-CI  ERR 95%-CI 
A. lumbricoides 
WHO Reference efficacy1   ≥95   ≥95 
Review main estimates2  98.5 94.9-100.0  98.0 94.0-100.0 
Review estimates for 19952  99.5 94.7-100.0  99.7 93.3-100.0 
Review estimates for 20152  95.4 88.2-100.0  94.8* 87.3-100.0 
Hookworm 
WHO Reference efficacy1   ≥90   ≥70 
Review main estimates2  89.6* 81.9-97.3  61.0* 52.0-69.9 
Review estimates for 19952  95.6 85.3-100.0  69.4* 54.3-84.6 
Review estimates for 20152  77.1** 62.5-91.7  51.8** 35.3-68.2 
T. trichiura 
WHO Reference efficacy1 <275 EPG3 
<550 EPG3 
 ≥903 
≥703 
  ≥50 
 
 <800 EPG3  ≥501,3    
Review main estimates2  49.9* 39.0-60.6  66.0 54.6-77.3 
Review estimates for 19952  72.6 53.7-91.5  91.4 72.9-100.0 
Review estimates for 20152  43.4* 23.5-63.3  54.7 34.6-74.8 
Table 6. World Health Organization reference efficacy (bold)  for albendazole and mebendazole and efficacy 
based our systematic review . 1WHO 2013 [5], 2Moser et al. 2017 [17], 3Vercruysse et al. 2011 [19] and Levecke 
et al. 2012 [30], *doubtful, **reduced 
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resistance or incorrect definition of the reference efficacies? A number of clinical trials reported 
reduced albendazole and mebendazole efficacy against hookworm and T. trichiura [19] and 
more recently of albendazole against A. lumbricoides [31]. However, these studies were either 
biased, based on wrong assumptions (e.g. for the assumed A. lumbricoides treatment failures a 
wrong follow up period was used) or failed to associate reduced efficacy with the presence of a 
resistance marker [28,31]. For Haemonchus contortus, a nematode with veterinary importance, 
benzimidazole resistance was associated with a single nucleotide polymorphism (SNPs) in the 
β-tubulin gene at three positions (codon 200, 167 and 198) [32]. Studies investigating the same 
SNPs in humans reported the finding of a single SNP in each STH species, e.g. at codon 167 
for A. lumbricoides and 200 for hookworm and T. trichiura [33,34]. After treatment with 
albendazole an increased frequency of SNPs in codon 200 of T. trichiura was observed, 
however, an association with reduced efficacy could not be confirmed [35]. For human STH, the 
benzimidazole mode of action and the number and place of SNPs responsible for resistance 
remain unknown. Hence, in a next step, the particular mode of action in human STH have to be 
studied to identify the SNPs associated with drugs resistance and with a potential to be used as 
resistance markers. For the final answer to the above stated question, a study showing reduced 
drug efficacy directly related to well-established resistance markers are needed, currently being 
undertaken in a Bill and Melinda Gates funded (Starworms) project. Until the association is 
proven, the current WHO reference efficacies should be revised based on the review conducted 
during this PhD-thesis. 
 
6.3.2. Application of drug efficacy measurement 
For calculating the ERRs, the key measurement in anthelminthic drug efficacy, two 
measurements of central tendency (MCT) are exclusively used; the arithmetic and geometric 
mean. Both have their limitation, for example, the arithmetic mean is heavily influenced by 
outliers, which led to decreased ERRs in the study of Speich et al. [8] from 73% compared to 
93% without the outlier at follow-up. The disadvantage of the geometric mean is the assumption 
of homogeneity of the variance between the compared group and the choice of the constant for 
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taking the logarithm of the zero egg counts at follow-up [36–38], which led to the 
recommendation of the arithmetic mean by the WHO [5]. Within this PhD thesis, we wanted to 
address the question about which MCT is preferable by using a completely new approach, 
however, the work is still in progress and not presented fully in this thesis.  
Using a questionnaire including different visualised distributions of helminth egg counts from 7 
randomised controlled trials [7,8,12,39–41], we asked a panel of experts (human and veterinary 
parasitologists/epidemiologists, and biostatisticians) to judge which of the two presented 
treatment arms is associated with a higher burden and efficacy (Figure 11). Two different 
definitions were used if the experts judged the worm burden or treatment efficiency higher in a 
certain trial arm: i) simple majority - more raters considered the burden/treatment efficiency 
higher compared to the other arm and ii) consent – 90% of the experts rated the 
burden/efficiency in a certain arm as better or similar, trial arm comparisons with an experts’ 
agreement below 90% were discarded. The response rate was 64% (49 from 76 experts 
returned a filled-in questionnaire). In addition, we calculated for all trial arms different MCTs - 
arithmetic, geometric, Hölder (with parameter 0.1-0.9), Lehmer (with parameter 0.1-0.9), 
truncated (0.02-0.1%) and Winsorized mean (0.02-0.1%). Agreement between raters and MCT 
was calculated as the proportion of comparisons favouring the same trial arm. The results of 
both definitions are presented in Figure 11.   
Against our expectations, the arithmetic mean showed lowest agreement and ranked last. The 
different truncations and Winsorizations indicated an improved agreement but were 
outperformed by the Lehmer mean, while the geometric and the Hölder mean (with parameter 
0.2) ranked at the top. Since the Hölder mean only slightly outperformed the geometric mean 
and since the work is still in progress it remains unclear, whether the slightly better performance 
of the Hölder mean justifies the increased complexity associated with calculation compared to 
the geometric mean.  
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Figure 11. Pictogram of work-flow (left figure) and performance (right figure) of different measures of central 
tendency for all answers and (first) and answers with high consent, i.e. 90% of the answers with similar of higher 
burden for the same treatment arm (right). 
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6.4. Review of old and new drugs 
Poor efficacy of the current drugs against T. trichiura and additionally, the lack of new drugs in 
case of benzimidazole resistance, are the major threats to the success of PC. Despite the 
depleted anthelminthic drug pipeline, a few new drugs are either evaluated by the US Food and 
Drug Administration (tribendimidine), pushed forward onto the WHO List of Essential Medicine 
for STH (ivermectin) or under research for their potential in PC programs (albendazole-
ivermectin). Since there is already quite some published evidence about the efficacy of 
tribendimidine, albendazole-oxantel pamoate and albendazole-ivermectin, the systematic review 
and network meta-analysis (chapter 3) was extended by including studies with the afore 
mentioned drugs. 
 
6.4.1. Extending the review with new anthelminthic drugs or combinations 
The literature search was extended up to 1 September 2017 and the terms “tribendimidine”, 
“oxantel pamoate”, “ivermectin”, “co-administration” and “combination” were added to the triple 
MeSH terms of the already published review and network meta-analysis [17]. The search 
resulted in the inclusion of five published [12,46–49] and one unpublished study including 
albendazole-oxantel pamoate [46] and several treatment arms of included studies became 
eligible, i.e. one with tribendimidine [47], two with albendazole-oxantel pamoate [7,8] and 5 with 
albendazole-ivermectin [8,41,48–50]. For increasing the number of studies, two different oxantel 
pamoate (20 and 25 mg/kg) and ivermectin (according to height and 200–400 µg) dosages were 
included and combined. The new network of the extended review is presented in Figure 12.  
Against A. lumbricoides, the CRs of all newly included treatments were similarly high (>95%) 
and, the ERRs of each new treatment arm were above 98% (Table 9). For treating hookworm 
infections, the CRs of albendazole-ivermectin (88.5%, 95% confidence interval, 70.0-96.2) were 
non-significantly higher compared to tribendimidine (80.8%, 63.3-91.1) and albendazole (77.7%, 
70.5-83.6). However, tribendimidine (92.4%, 75.2-100.0) showed marginally increased ERRs in 
contrast to albendazole monotherapy (89.9%, 81.7-98.1), while the ERRs of the combination 
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albendazole with oxantel (85.7%, 68.7-100.0) or ivermectin (85.4%, 68.0-100.0) were slightly 
lower. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tribendimidine had no effect against T. trichiura and the CR (3.2%, 0.5-18.2) and ERR (12.4%, 
-8.3-33.0) were even lower than for the placebo. The CR of albendazole-oxantel pamoate 
(75.0%, 44.8-91.7) against T. trichiura was significantly higher compared to albendazole 
(p=0.004), mebendazole (p=0.045), pyrantel pamoate (p=0.003), tribendimidine (p<0.001) and 
not significantly higher to albendazole-ivermectin (57.1%, 37.6-74.6). Albendazole-ivermectin 
showed significantly higher CRs against T. trichiura compared to albendazole (p=0.004), 
pyrantel pamoate (p=0.009) and tribendimidine (p<0.001). The ERRs of the combination 
albendazole plus oxantel pamoate (93.6%, 79.3-100.0) or ivermectin (91.0%, 78.3.-100.0) were 
significantly higher against T. trichiura compared to any mono-therapy (p<0.01).  
Since the anthelminthic drug efficacy contains two different measures, i.e. CRs and ERRs, the 
drugs could not be ranked by the network meta-analysis [14]. Therefore, a simpler ranking of  
Figure 12. Updated flow chart and network. 
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the CRs and ERRs was done as presented in Table 8. Since the ERRs are a more important 
indicator, the weight was doubled when taking the average of both (CR and ERR). A ranking 
was done for each helminth species and the final ranking including all three species. For A. 
lumbricoides all drugs and combinations reached similar high efficacy with only slight 
differences. Tribendimidine ranked first among all treatments against hookworm, followed by 
albendazole in combination and monotherapy. Against T. trichiura the best treatment was 
albendazole-oxantel pamoate, followed by albendazole-ivermectin and mebendazole, while the 
other single-drug regimens had much lower efficacies.  
In the final combined ranking, the two combinations, albendazole plus oxantel pamoate or 
ivermectin, outreached all monotherapies and shared the first place. Considering only 
hookworm and T. trichiura, albendazole-oxantel pamoate would slightly outcompete 
albendazole-ivermectin. The two most widely used drugs albendazole and mebendazole, 
followed on rank 3 and 4, respectively. Despite tribendimidine reaching the first place for 
Treatment Cure rates  Egg reduction rates 
No. 
studies 
No. 
subjects Rate         (95%CI) 
 No. 
studies 
No. 
subjects 
 
Rate            (95%CI) 
Ascaris lumbricoides 
PLC 14 842 12.3 6.6-21.7  9 525 20.8 15.3-26.3 
ALB 35 3410 95.9 93.6-97.3  27 2904 98.5 95.3-100.0 
MEB 13 1548 96.1 92.4-98.0  13 1529 98.0 94.3-100.0 
LEV 2 149 97.2 84.7-99.5  1 125 96.6 83.7-100.0 
PYP 11 1374 92.5 85.8-96.2  6 284 94.2 88.8-99.7 
TRB 3 125 96.2 80.6-99.4  4 125 99.8 87.5-100.0 
ALB-OXP 4 312 95.5 84.9-98.8  4 312 98.9 91.6-100.0 
ALB-IVR 4 242 95.9 84.6-99.0  4 242 99.3 92.2-100.0 
Hookworm 
PLC 18 1309 14.7 9.3-22.4  14 1046 15.8 5.6-26.0 
ALB 34 3392 77.7 70.5-83.6  28 3024 89.9 81.7-98.1 
MEB 14 2305 33.1 22.2-46.1  14 2263 60.4 50.4-70.3 
LEV 2 230 10.6 2.8-33.3  1 202 61.6 26.5-96.7 
PYP 7 230 48.8 29.8-68.2  5 144 70.5 51.6-89.3 
TRB 6 465 80.8 63.3-91.1  5 363 92.4 75.2-100.0 
ALB-OXP 4 395 66.1 38.6-85.6  4 395 85.7 68.7-100.0 
ALB-IVR 4 279 88.5 70.0-96.2  4 279 85.4 68.0-100.0 
Trichuris trichiura 
PLC 11 1417 9.8 5.3-17.7  8 1049 19.7 7.9-31.4 
ALB 32 4492 30.5 51.4-41.4  29 3467 50.6 40.7-60.6 
MEB 13 2514 42.6 27.7-59.0  14 2507 70.1 59.4-80.7 
LEV 2 203 28.7 6.8-68.9  1 197 37.4 16.7-58.1 
PYP 6 275 19.3 7.5-41.1  4 158 54.8 31.9-77.6 
TRB 3 158 3.2 0.5-18.2  3 158 12.4 -8.3-33.0 
ALB-OXP 4 519 75.0 44.8-91.7  4 519 93.6 79.3-100.0 
ALB-IVR 5 508 57.1 37.6-74.6  4 491 91.0 78.3-100.0 
Table 7. Updated network meta-analysis and including placebo (PLC), albendazole (ALB), mebendazole (MEB), 
levamisole (LEV), pyrantel pamoate (PYP), tribendimidine (TRB), albendazole-oxantel pamoate (ALB-OXP) and 
albendazole-ivermectin (ALB-IVR). 
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treating A. lumbricoides and hookworm, it has no effect against T. trichiura and was therefore 
ranked only on 6th place in the final ranking. 
 
Whereas the review published during this PhD thesis [17] highlighted the low efficacy of 
albendazole and mebendazole against T. trichiura and decreased efficacy over time, the 
extended review of this chapter demonstrated the increased efficacy of drug combinations. The 
two most promising drug combinations albendazole plus oxantel pamoate or ivermectin, 
revealed superior efficacy over single-dose regimens for the simultaneous treatment of the three 
STH species. Therefore, drug combinations instead of single-drugs should be used in PC 
programs. 
 
6.5. Efficacy of the tested drugs 
The main goal for the three clinical trials of this PhD thesis was further development of oxantel 
pamoate. First, a weight-independent oxantel pamoate regimen was determined through a 
dose-finding trial. In the second trial, oxantel pamoate was combined with another new drug, 
tribendimidine. In the third clinical trial, the improved efficacy of the TDT albendazole-pyrantel-
oxantel pamoate was validated. The subordinate goal was to assess the new Chinese drug 
tribendimidine, which was for the first time evaluated in combination with other drugs and in an 
African setting. 
Treatment 
A. lumbricoides  Hookworm  T. trichiura Final 
Rank 
CR ERR 
R
a
n
k  
CR ERR 
R
a
n
k  
CR ERR 
R
a
n
k 
Placebo 12.0 20.0 8 14.7 15.8 8 9.8 19.7 7 8 
Albendazole 95.9 98.5 4 77.7 89.9 3 30.5 50.6 4 3 
Mebendazole 96.1 98.0 5 33.1 60.4 6 42.6 70.1 3 4 
Levamisole 97.2 96.6 6 10.6 61.6 7 28.7 37.4 6 7 
Pyrantel pamoate 92.5 94.2 7 48.8 70.5 5  19.3 54.8 5 5 
Tribendimidine 96.2 99.8 1 80.8 92.4 1 3.2 12.4 8 6 
Albendazole-oxantel pamoate 95.5 98.9 3 66.1 85.7 4 75.0 93.6 1 1 
Albendazole-ivermectin 95.9 99.3 2 88.5 85.4 2 57.1 91.0 2 1 
Table 8. Extended review of the current anthelminthic drugs, a ranking attempt. Traffic light colours are used to 
indicate the best (green) up to worst (red) treatments. 
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6.5.1. Comparing the drug efficacy from three clinical trials 
In 1974, oxantel pamoate was introduced on the market [51], examined in combination with 
pyrantel pamoate in multiple clinical trials [52] and approved in several countries (Quantrel; 
Pfizer). Because of the depletion of the anthelminthic drug pipeline, oxantel pamoate had its 
‘comeback’ in the laboratory of the Group from Prof Jennifer Keiser [53,54] and later on, in two 
clinical trials led by Speich and colleagues [7,8]. In this PhD-thesis, the development of oxantel 
pamoate was carried further with a dose-finding study and combination trials. Our dose-finding 
trial included regimens from 5 to 30 mg/kg in order to investigate a weight-independent dose. 
Considering oxantel pamoate is used for PC in the future and millions of doses would be 
administrated every year, a weight-independent tablet is pivotal for optimizing the delivery 
process.  
While oxantel pamoate has a high trichuricidal and no activity against A. lumbricoides and 
hookworm, tribendimidine offers high activity against the two latter helminth species. The 
objective of the second trial was to assess tribendimidine in African settings and to evaluate the 
potential of tribendimidine in combination with other drugs against all three STH. Considering 
the possibility of anthelminthic resistance against albendazole and mebendazole, tribendimidine 
could complement albendazole in PC programs or replace it in the case of resistance. The 
advantage of combination chemotherapy presents the increased efficacy over single-dose 
treatments and the mitigates drug pressure of the current anthelminthics [19]. The last clinical 
trial of this PhD-thesis had a similar objective, for example, evaluating the increased efficacy 
against hookworm by adding pyrantel pamoate to the currently most efficacious combination 
albendazole-oxantel pamoate.  
The CRs and ERRs (i.e. arithmetic and geometric) of the three clinical trials are summarized in 
Table 9. For oxantel pamoate the dose-finding results of only two doses are presented (20 
mg/kg and 25 mg/kg). The final ranking included placebo, oxantel pamoate and tribendimidine 
as single drug regimens and six different drug combinations. For estimating the most efficacious 
treatment among the three clinical trials, the average of the CRs and the arithmetic and 
geometric ERRs was ranked from 1 to 11. To increase the weight of the ERRs, the results 
Chapter 6 – General Discussion  PhD-thesis W. Moser 2017 
 
127 
 
based on the arithmetic and geometric mean were included (table 9). Of note, the three trials 
were conducted in different settings and age groups with varying infection intensities. Hence, for 
a final conclusion, which treatment to include in PC programs, the multicontinental head to head 
comparisons might be considered (Table 9).  
All single-drugs, co-administrations and triple drug therapies reached a high efficacy against A. 
lumbricoides, except oxantel pamoate, which had no effect. Thus, it is not surprising that oxantel 
pamoate and placebo are found at the bottom of the ranking. In contrast, pyrantel-oxantel 
pamoate and the mebendazole TDT cured all participants and therewith shared the first rank. 
For the remaining treatments ERRs of 99.9% or slightly below were observed and the ranking 
between palace 1 and 8 was defined by only slight differences.  
For treating hookworm infections, the albendazole TDT outreached any other treatment. Despite 
a four times higher infection intensity (geometric EPG: 671 versus 166), higher geometric 
(99.9%) and arithmetic ERRs (98.4%) were reached compared to the second ranking co-
administration, tribendimidine plus ivermectin (geometric 99.5%, arithmetic 96.3%). The TDT  
with mebendazole ranked third and pyrantel-oxantel pamoate fourth. Whereas the CRs of the 
mebendazole TDT were clearly higher (69.6% versus 52.2%), the ERRs were lower based on 
the arithmetic (96.3% versus 95.9%), and higher according to the geometric mean (99.2% 
versus 99.6%). Surprisingly, albendazole-oxantel pamoate reached higher efficacy against 
hookworm in the Asian setting (rank 5) compared to the African setting (rank 6) regardless of 
the more than three times higher baseline infection intensity (geometric EPG: 707 versus 195). 
Tribendimidine plus oxantel pamoate or as single-drug, followed on the rank 7 and 8, 
respectively. Nonetheless, the tribendimidine trial (chapter 4a) showed non-inferiority for 
tribendimidine-oxantel pamoate (rank 7) and albendazole-oxantel pamoate (rank 6).  
Against T. trichiura, all oxantel pamoate co-administrations ranked first, followed by the mono-
therapies, whereas placebo ranked before tribendimidine. In the clinical trial in Laos, all children 
receiving albendazole-oxantel pamoate were cured and three children remained positive after 
treatment with albendazole or mebendazole TDT. Nevertheless, the comparison between the 
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two combination trials (chapter 4a and 4b) is restricted by the more than 7 times lower infection 
intensity in the Laos trial. The results from two oxantel-pamoate studies of Speich and 
colleagues [7,8] already indicated an improved efficacy with lower infection intensity, which 
might be driven by the increased efficacy of albendazole for lower infection intensities [30]. 
Comparison of pyrantel-oxantel pamoate (rank 6) with both oxantel pamoate dose regimens 
(rank 7 and 8), indicates the only low efficacy of pyrantel pamoate against T. trichiura, which 
was supported by the results of the review [17].  
The review indicated the lack of the current drugs against T. trichiura. However, the results of 
the three trials conducted during this PhD thesis highlighted that; i) oxantel pamoate has high 
activity against T. trichiura and could be given at a dose of 500 mg, ii) tribendimidine and 
pyrantel pamoate are valuable candidates against hookworm, iii) co-administrations reach high 
efficacy against any STH species and iv) TDTs have highest CRs and ERRs among all tested 
treatments.  
Since the current goal of WHO is to control STH infections by reducing moderate and heavy 
infection intensities an ideal treatment requires a high ERRs and a fast administration (weight-
independent dose). Two combinations fulfil the required criteria; albendazole (400 mg) plus 
oxantel pamoate (500 mg) and tribendimidine (200/400 mg) and oxantel pamoate (500 mg). 
After a thorough dose-finding study of ivermectin (currently in progress) and pyrantel pamoate, 
two additional co-administrations would fulfil the above-mentioned criteria: tribendimidine plus 
ivermectin and pyrantel plus oxantel pamoate. However, before adding tribendimidine and 
oxantel pamoate on the WHO Model List of Essential Medicine, an FDA approval is needed.  
Once the control of STH infections is reached and the strategy shifts towards STH elimination, 
the higher CRs of the two evaluated TDTs (albendazole-pyrantel-oxantel pamoate and 
mebendazole-pyrantel-oxantel pamoate) could become valuable. A similar strategy is currently 
applied for the elimination of lymphatic filariasis, i.e. the use of a TDT (albendazole-ivermectin-
diethylcarbamazine) which is included in the latest WHO guidelines [55] and promising 
outcomes have been modelled [56].  
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6.6. Preventive chemotherapy – a debate and outlook 
This PhD thesis could have a considerable impact on PC recommendations. First, the results 
from the review (chapter 2a) and the recommendations of the measure of central tendency 
(Hölder or geometric mean) compel the need for adaption of the current WHO guidelines. 
Second, the clinical trials (chapter 3, 4a and 4b) demonstrated the high efficacy of the drugs, 
oxantel pamoate, pyrantel pamoate and tribendimidine and highlighted the improved efficacy of 
drug combinations. All these facts underline the necessity of including new drugs on the 
Essential List of Medicine against STH and the change to combination chemotherapy. In this 
sub-chapter, the advantages and disadvantages of PC are discussed and the next steps for the 
successful continuation of STH control programs are presented.  
 
6.6.1. Does preventive chemotherapy have a benefit? 
Mass drug administration has been the main strategy against STH since the endorsement by 
the World Health Assembly in 2001 [57]. The term “preventive chemotherapy” was introduced 
by WHO for mass drug administration against helminth infections [58]. However, the outcome of 
PC is controversially discussed, with no less than eight different reviews on this topic within the 
three last years (Table 11).  
Two Cochrane reviews from 2015 revealed no improvement in anaemia, birth weight etc. in 
pregnant women (after the second and third trimester) [59] and a weight and height gain in 
children with a confirmed infection (only children diagnose with an infection) and no gain for 
children with an unknown infection (infected and uninfected children) after PC [60]. However, 
several concerns about the methodology were raised and addressed in two further reviews 
[61,63]. The first review published by the World Bank showed a weight gain for infected children 
in endemic settings (prevalence ≥20%) and calculated that PC is 35 times more cost-effective 
than school feeding programs [61]. In contrast, a second review from the Campbell 
Collaboration [63] demonstrated no improvement in weight, height, stunting, cognition, school 
attendance and mortality for children after PC. The impact of anthelminthics on HIV co-
Chapter 6 – General Discussion  PhD-thesis W. Moser 2017 
 
131 
 
infections showed a short-term suppression of the viral load, while the evidence about a long-
term suppression is lacking [62]. PC was able to reduce the STH prevalence in school-aged 
children [63] and non-pregnant adolescent girls and women (Welch et al., unpublished, data 
shown in WHO guidelines [18]). Additionally, the prevalence of A. lumbricoides and hookworm 
significantly decreased after community-wide PC compared to targeted PC (only children) [64] 
and more importantly, a high reduction of moderate and heavy infections for any STH was 
demonstrated by Marocco and colleagues [65]. 
 
The Cochrane reviews [60,66] have been profoundly criticized; among other reasons, because 
they included only randomised controlled trials (RCT) which evaluate the effect over a short 
period (12 month) [60], long term studies were excluded and pooled data of infected and 
Reference Objective Pro 
 
Contra 
Salam 
2015 
[59]1 
Impact of anthelminthics 
in pregnant women (2&3 
trimester) on anaemia 
and pregnancy 
 - Single dose has no impact on maternal 
anaemia, low birth weight, preterm birth 
and perinatal mortality 
 
Taylor-
Robinson 
2015 
[60]1 
 
Impact of PC on 
children’s weight, height, 
haemoglobin, cognition, 
physical well-being, 
school attendance/ 
performance mortality 
- Confirmed infection in children: weight 
and height gain 
 
- Confirmed infection in children: no 
difference in haemoglobin, body mass 
index etc. 
- Unknown infection in children: no effect 
on weight, height, haemoglobin, average 
cognition for children  
Croke 2016 
World bank 
[61]3 
impact of PC on child 
growth  
- Confirmed and unknown infection in 
children: weight gain in endemic settings 
(prevalence >20%) 
- PC 35 times more effective on weight 
gain than school feeding programs 
 
 
Means 
2016 
[62]1 
Impact of anthelminthics 
on HIV disease 
progression 
-Confirmed infection: short-term 
suppressive effect on mean viral load 
- no additional risk of anthelminthics on 
HIV-population 
- Unknown infection: maybe little short 
and long-term effect on viral load 
Welch 
2017 
[63]2 
Impact of PC on health 
and performance 
outcome of school-aged 
children 
- only minimal adverse effects due to PC 
- PC was able to reduce prevalence of all 
STH 
- No evidence of improved weight, height, 
stunting, cognition (attention, general 
intelligence and mathematical 
achievements), school attendance and 
mortality after PC 
Clarke 
2017 
[64]4 
Impact of targeted 
(school-children) versus 
community-wide PC on 
prevalence 
- Prevalence reduction is significant 
higher after PC compared to targeted 
treatment for A. lumbricoides and 
hookworm in school-aged children 
- No effect was seen for T. trichiura, 
maybe because of low efficacy of the 
available drugs 
 
Marocco 
2017  
[65]4 
Impact of PC on 
moderate and heavy 
infected  
- The reduction of moderate and heavy 
infection was 80%, 57% and 75% after 1 
year and 90%, 100% and 78% after 5 
years for A. lumbricoides, hookworm and 
T. trichiura, respectively 
 
Welch 
unpublishe
d [18]2 
Impact of PC on non-
pregnant adolescent girls 
and women 
- Lower STH prevalence after treatment 
- All drugs are safe 
- No difference in anaemia, iron-
deficiency anaemia and morbidity 
Table 11. Most recent systematic reviews and meta-analysis about the advantages and disadvantages of PC against soil-
transmitted helminths. 1 Cochrane review, 2 Campbell Collaboration, 3 World Bank, 4 Other 
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uninfected children diluted the effect [67]. Only a few outcomes were investigated and 
improvement of immediate (diarrhoea and abdominal pain) and long-term symptoms (e.g. 
cancer portal hypertension and infertility) were neglected [68]. The aim of Welch and colleagues 
[63] was to address the criticism of the previous reviews but they obtained a similar results. 
However, they failed to correctly address all the points mentioned above and therefore, the 
debate about the benefits of PC persists [68].  
The essential question about PC is: do we accept to treat all children, while only moderate and 
heavy infected children profit directly from PC? This question can be answered asking two 
additional questions first: i) does the drug harm uninfected children and ii) is the cost of mass 
treatment larger than screening and treating individuals. Since the answer to both questions is 
no [68,69], PC programs were implemented with the goal of reducing moderate and heavy 
infections, which are known to cause the highest disease burden [2,70]. Hence, the Cochrane 
and Campbell reviews failed to address the main question, whether PC was able to reduce 
moderate and heavy infections. Only one review answered this question adequately and 
reported a large reduction of any moderate and heavy STH infections by 73% after one, 80% 
after five and 95% after 10 years [65]. Subsequently, more specified sub-questions should 
include, for example, the impact of PC on parameters like weight, height, haemoglobin, 
cognition etc., which was turned into the main question by in the Cochrane and Campbell 
reviews. Moreover, the effect of PC on specific parameters is obviously diluted, first, by pooling 
uninfected and infected children regardless of the intensity and second, by considering only 
short-term studies [67]. In conclusion, to correctly address the sub-questions the next review 
should focus on aforementioned parameters from moderate and heavy infected children after 
one, two or more years of PC for drawing final conclusion about the benefit of PC.  
 
6.6.2. Next steps for STH control 
Coming to the end of my PhD, I would like to look forward and describe the next steps for PC. 
Nevertheless, first it is time to look back by “learning from history” as stated by John Horton [71]. 
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Despite high prevalence and non-existence of appropriate drugs, J.D. Rockefeller Jr was able to 
control hookworm infections with treatment and sanitation [71]. Moreover, after World War II 
Japan experienced high STH prevalence of over 50% for A. lumbricoides and T. trichiura [72]. 
STH control gained national priority and through improved sanitation, water supply, education, 
improved economic status and deworming, STHs were eliminated within 15-20 years [71,72]. A 
similar success story was reported from South Korea, in 1969 the STH prevalence reached 77% 
and compelled the government to set the focus on STH control. Bi-annual mass treatment of 
school-aged children, economic development, social infrastructure and improved sanitation over 
25 years led to a massive decrease in prevalence to 0.2% in 1995 [73].  
STH control is a product of behavioural changes, public consent and PC. As witnessed from 
history, STH control is achievable only through a combined effort. Behavioural change in the 
light of water and sanitation is a complex interaction between psychological factors and 
corresponding interventions [74]. The change embraces the in-depth understanding of the 
individual up to the community level and is a long-standing process with many pitfalls [75]. In 
2015, WHO encouraged the integration of water sanitation and hygiene (WASH) for targeting 
neglected tropical diseases, which include STH [76]. Much time, effort and research is needed 
for a successful implementation of a combined control approach [77]. Equally, the public 
consent is a slow process and demands the social agreement for allocating the required 
resources for helminth control [73]. However, resources in STH endemic countries are limited 
and priority is given to greater public health problems (i.e. malaria, HIV-Aids, tuberculosis etc.). 
Whereas behavioural change and public consent are complex and a long-standing process, PC 
is less convoluted. This PhD thesis showed that the current drugs are insufficient in successfully 
treating all three STH, while we have demonstrated the high efficacy of two potential drug 
candidates against A. lumbricoides and hookworm (tribendimidine) and T. trichiura (oxantel 
pamoate) or in combination against all three STH species. Drug combinations have an improved 
efficacy against any STH species, as highlighted in this discussion. Hence, research has 
provided new tools and it’s time for global health authorities to move forwards by adapting the 
guidelines and extending PC. For example, tribendimidine is currently under assessment 
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towards the approval by the FDA [78]. Once the approval is granted and WHO has added 
tribendimidine on the Essential List of Medicine against STH, an agreement with the producing 
pharmaceutical company Shandong Xinhua (Zibo, Shandong, China) could lead to 
tribendimidine donations for PC. The development of oxantel pamoate trails behind, since Pfizer 
stopped the production. For completing the same process, a pharmaceutical company willing to 
produce the tablets at very low cost has to be identified. History has demonstrated that with an 
integrated approach combining health education together with improved WASH and new drugs 
for PC, control of STH is feasible.  
 
6.7. Further steps for diagnostics 
The foundation of STH research, e.g. the collection of data on distribution, prevalence, intensity 
or drug efficacy builds on accurate diagnostic tools. Through different steps from the initial 
mapping over morbidity and transmission control up to the elimination of STH, different 
diagnostic attributes are required [79]. However, in helminth diagnostics there is a trade-off 
between sensitivity and time or cost-effectiveness, meaning cheap and fast tools have a low 
sensitivity compared to expensive and time-intensive methods with high sensitivity. Diagnostic 
methods with lower sensitivity are acceptable for large scale mapping in order to identify priority 
areas. Moving from transmission control to surveillance or even elimination, the correct 
identification of light or even micro-infections gain importance and hence, higher sensitivity are 
required.  
 
6.7.1. Helminth diagnostics: available tools, limitations and further steps 
Among well-established diagnostic tools (Table 12), Kato-Katz remains the recommended 
technique by the WHO for analysing STH in human stool [5]. Kato-Katz is used since almost 
half a century because of its simplicity, low cost and short preparation time and quantification of 
eggs in stool [11]. Within a half an hour a duplicate Kato-Katz is performed and it costs only 
about 0.04 US$ [80]. The major disadvantage of Kato-Katz is the low sensitivity for low infection 
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intensity, i.e. the correct identification of positive individuals with a very light infection. In low 
intensity settings, the sensitivity can be increased by analysing a second slide or second sample 
[81], which also accounts for the day-to-day variation in egg output [82]. Further limitations 
involve the disappearance of hookworm eggs after one hour [83], the incapability of storing stool 
samples [84] and the desiccation of the prepared Kato-Katz slides.  
 
Method Advantages Limitations Sensitivity 
Copro-microscopic diagnostic methods 
K
a
to
-K
a
tz
 
(2
 s
li
d
e
s
) - little equipment and fast preparation, field 
deployable 
-relatively inexpensive 
-good sensitivity for moderate and heavy 
infections 
- low sensitivity for light infections 
- time sensitive (i.e. for hookworm only 60 min) 
- not accounting for day-to-day variation 
A 55.2-97.01 
H 52.6-74.01 
T 79.8-95.31 
D
ir
e
c
t 
M
ic
ro
. - little equipment 
- very fast analysis 
- field deployable  
- only qualitative  
- low sensitivity 
- not accounting for day-to-day variation 
A 39.21 
H 16.3-53.71 
T 14.91 
E
th
e
r-
c
o
n
c
e
n
tr
a
ti
o
n
 
-good sensitivity for moderate and heavy 
infections 
- diagnosis of STH and intestinal protozoa 
-preservation of samples 
 
 
- only qualitative 
- requires centrifugation, sedimentation and 
formalin solutions 
 
A 51.31 
H 38.91 
T 21.51 
F
L
O
T
A
C
 
- little equipment, field deployable 
- relatively inexpensive 
-good sensitivity for moderate and heavy 
infections 
- preservation possible, not time sensitive  
- requires centrifugation, flotation and formalin 
solution 
- low sensitivity for light infections (better than 
the others) 
- long preparation time 
- not accounting for day-to-day variation 
A 81.8-97.11 
H 68.8-98.11 
T 85.7-99.61 
M
in
i-
F
L
O
T
A
C
 - little equipment, field deployable 
- relatively inexpensive 
-good sensitivity for moderate and heavy 
infections 
- preservation possible, not time sensitive 
- low sensitivity for light infections 
- not accounting for day-to-day variation 
- requires flotation and formalin solution 
- lower egg counts are underestimates the true 
burden and influence the ERRs 
A 47.11 
H 44.3-97.31 
T 58.31 
M
c
M
a
s
te
r - little equipment, field deployable 
- very fast analysis, inexpensive 
-good sensitivity for moderate and heavy 
infections 
- easier reading compared to Kato-Katz 
- low sensitivity for light infections 
- not accounting for day-to-day variation 
- requires flotation solution 
 
A 48.9-94.71 
H 34.5-69.71 
T 75.5-90.41 
F
E
C
P
A
K
G
2
 
- storage of the result in form of an image 
(jpeg) 
- mark-up at later stage possible 
 
- by now, low sensitivity 
- depends on quality of captured images 
- not accounting for day-to-day variation 
- (needs further improvement) 
 
A 75.52 
H 68.02 
T 65.72 
Copro-molecular diagnostic methods 
q
P
C
R
 
- frozen material can be used 
- Good sensitivity for light infection 
- Analysing different parasites 
 (multiplex qPCR) 
- High throughput  
- semi-quantitative 
- correlation between DNA level and number of 
worms or eggs not yet established  
- DNA from nonviable might give signal 
- requires infrastructure and thermocycler  
A 85.7-100.03 
H 75.7-100.03 
T 100.03 
L
A
M
P
 - frozen material can be used 
- field deployable  
- relatively fast, little equipment 
- Semi-quantitative  
- Uses a minimum of 4 specific primers  
- not yet developed for T. trichiura 
A 96.34 
H 97.04 
T - 
Table 12. The different diagnostic methods, their advantage and disadvantage and sensitivity (A, Ascaris 
lumbricoides; H, Hookworm; T, Trichuris trichiura). 1Nikolay et al. 2014 (review) [81], 2Moser et al. 2017, 
unpublished, 3O’Connel and Nutman (review) [85], 4Shiraho et al. 2016 [86] 
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Among all copro-microscopic methods direct microscopy has the lowest sensitivity, followed by 
the ether-concentration technique [81,87]. Both techniques are only qualitative; hence they are 
unemployable for assessing infection intensities or drug efficacy. McMaster has shown similar 
sensitivity and egg recovery rates compared to Kato-Katz [29,88]FLOTAC has highest 
sensitivity amongst the copro-microscopic methods and is less affected by infection intensity 
[81], indicating its potential for transmission control [79]. Yet, FLOTAC requires a centrifuge, 
longer time for sample preparation, expensive equipment and an additional ether washing step 
[89]. Consequently, mini-FLOTAC was developed by the same team, which is a simplified 
method of FLOTAC [90]. On the downside, the simplification came along with a lower sensitivity, 
which is no longer superior to Kato-Katz [81,91].  
Within this PhD thesis, FECPAKG2, a new remote-location, online diagnostic tool was assessed 
for qualitative and quantitative parameters within a clinical trial. Although lower sensitivity and 
number of recovered eggs was shown for FECPAKG2 compared to Kato-Katz (Chapter 5a), the 
sensitivity was high for moderate infection intensity and the estimated ERRs were indiscernible 
from Kato-Katz. Since WHO aims to reduce the burden attributed to moderate and heavy 
infection by 2020 [2], FECPAKG2 is a suitable tool to correctly identify these infections. 
Moreover, FECPAKG2 offers several advantages including capturing of an image, which can be 
stored on a computer and uploaded onto a cloud once an internet connection is established.  
In comparison, stool samples can be preserved with mini-FLOTAC for 15 days [92], but not with 
Kato-Katz [84]. For Kato-Katz, the stool samples have to be prepared within three hours after 
collection to avoid a substantial sensitivity drop [84] and analysed within one hour to evade the 
disappearance of hookworm eggs [83], leaving only a short time window for quality control [93]. 
By applying FECPAKG2 under field conditions, a larger number of samples can be prepared, 
stored, uploaded and analysed at a later time point to shorten the study duration. Anytime, 
anywhere, the uploaded image can be accessed and processed with computer software. For 
quality control or in case of discrepancies, specialists around the world can be consulted. Efforts 
are being made to develop an image-analyse algorithm for the automatic counting of STH eggs, 
which would lead to many grateful researchers spending endless hours in front of a microscope 
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and counting thousands of eggs. In the upcoming studies, the cost-effectiveness and the 
sample preparation time should be compared to current established diagnostic methods.  
Apart from new field deployable methods, the future of STH diagnostics are highly sensitive 
molecular methods, for example, quantitative polymerase chain reaction (qPCR) and loop 
mediated isothermal amplification (LAMP). In settings with declining infection intensities, moving 
from transmission control to surveillance or elimination, qPCR is able to detect micro-infections 
without the constraint of the day-to-day variation. Moreover, multiplex qPCRs are able to 
estimate infection intensities [94] and result in the concomitant diagnosis of multiple parasites, 
which is of particular interest for routine screening in hospitals and for research in settings with 
different hookworm species [94,95]. Whereas the sensitivity of qPCR is higher compared with 
any copro-microscopic methods [85], the major drawbacks are the required laboratory 
equipment, inhibition of PCR product amplification by stool substances, decreased sensitivity 
due to preservation solvents [85], residual DNA [96] and a higher cost. The expenses for one 
qPCR, including the analysis of eight parasites at once, is less than 1$ [97] compared to 0.04$ 
for one Kato-Katz [80], given all equipment is present. Another molecular method is LAMP, an 
inexpensive, field deployable, highly sensitive method, which produces a visible result and 
requires only a heat block or water bath [98]. LAMP still needs further development, for 
example, infection intensities are not yet accurately reflected and LAMP was only developed for 
A. lumbricoides [86] and N. americanus [98] in laboratory and not yet evaluated under field 
conditions.  
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Conclusion 
Every fifth person in the world is infected with at least one soil-transmitted helminths species; 
nonetheless, they remain neglected by health and policy makers in most of the endemic 
countries. Preventive chemotherapy – the administration of anthelminthic drugs to at risk 
populations is the current strategy and was the general topic of this PhD thesis. First, the 
currently available drugs used for preventive chemotherapy were reviewed and their efficacy 
meta-analysed. Our findings indicate the shortcomings of the two mainly used drugs 
albendazole and mebendazole, in particular against T. trichiura and their decreased efficacy 
over time. Moreover, we presented the first-time summary estimates of the egg reduction rates, 
the key measure of anthelminthic drug efficacy and recommended use of geometric mean 
based on expert’s opinion. Both results call for an adaption of the current guidelines, first, for 
monitoring anthelminthic drug resistance and second, for the calculation of egg reduction rates.  
The review highlighted the need for new drugs with high efficacy against T. trichiura and against 
any soil-transmitted helminths in case of drug resistance. In the three clinical trials, we 
investigated two new drugs: oxantel pamoate and tribendimidine. First, a weight-independent 
dose of oxantel pamoate against T. trichiura was evaluated, for accelerating the process of drug 
administration in preventive chemotherapy. Second, tribendimidine in combination (with 
ivermectin or oxantel pamoate) was compared to albendazole-oxantel pamoate against 
hookworm. Third, the improved efficacy for treating hookworm infections by adding pyrantel 
pamoate to the combination albendazole-oxantel pamoate was studied. The results highlight the 
high efficacy of oxantel pamoate against T. trichiura and tribendimidine and pyrantel pamoate 
against A. lumbricoides and hookworm. Moreover, the combinations were able to successfully 
treat all three soil-transmitted helminth species at once, which call for an adaption of the WHO 
guidelines towards the use of combination for preventive chemotherapy.  
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